

Modeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape

Genevieve Kunkel,¹ Mohammad Madani,¹ Simon J. White,² Paulo H. Verardi,³ and Anna Tarakanova^{1,4,*}

¹Department of Mechanical Engineering, ²Department of Molecular and Cell Biology, ³Department of Pathobiology and Veterinary Science, and ⁴Department of Biomedical Engineering, University of Connecticut, Storrs, Connecticut

ABSTRACT The ongoing COVID-19 pandemic is a global public health emergency requiring urgent development of efficacious vaccines. While concentrated research efforts have focused primarily on antibody-based vaccines that neutralize SARS-CoV-2, and several first-generation vaccines have either been approved or received emergency use authorization, it is forecasted that COVID-19 will become an endemic disease requiring updated second-generation vaccines. The SARS-CoV-2 surface spike (S) glycoprotein represents a prime target for vaccine development because antibodies that block viral attachment and entry, i.e., neutralizing antibodies, bind almost exclusively to the receptor-binding domain. Here, we develop computational models for a large subset of S proteins associated with SARS-CoV-2, implemented through coarse-grained elastic network models and normal mode analysis. We then analyze local protein domain dynamics of the S protein systems and their thermal stability to characterize structural and dynamical variability among them. These results are compared against existing experimental data and used to elucidate the impact and mechanisms of SARS-CoV-2 S protein mutations and their associated antibody binding behavior. We construct a SARS-CoV-2 antigenic map and offer predictions about the neutralization capabilities of antibody and S mutant combinations based on protein dynamic signatures. We then compare SARS-CoV-2 S protein dynamics to SARS-CoV and MERS-CoV S proteins to investigate differing antibody binding and cellular fusion mechanisms that may explain the high transmissibility of SARS-CoV-2. The outbreaks associated with SARS-CoV, MERS-CoV, and SARS-CoV-2 over the last two decades suggest that the threat presented by coronaviruses is ever-changing and long term. Our results provide insights into the dynamics-driven mechanisms of immunogenicity associated with coronavirus S proteins and present a new, to our knowledge, approach to characterize and screen potential mutant candidates for immunogen design, as well as to characterize emerging natural variants that may escape vaccine-induced antibody responses.

SIGNIFICANCE We present novel, to our knowledge, dynamic mechanisms of coronavirus S proteins that encode antibody binding and cellular fusion properties. These mechanisms may offer an explanation for the widespread nature of SARS-CoV-2 and more limited spread of SARS-CoV and MERS-CoV. A comprehensive computational characterization of SARS-CoV-2 S protein structures and dynamics provides insights into structural and thermal stability associated with a variety of S protein mutants. These findings allow us to make recommendations about the future mutant design of SARS-CoV-2 S protein variants that are optimized to elicit neutralizing antibodies and resist structural rearrangements that aid cellular fusion and are thermally stabilized. The integrated computational approach can be applied to optimize vaccine immunogen design and predict escape of vaccine-induced antibody responses by SARS-CoV-2 variants.

INTRODUCTION

The recent coronavirus disease 2019 (COVID-19) global pandemic has highlighted that coronaviruses pose a dangerous threat to humans and animals. An important

feature of coronaviruses is their ability to adapt to new hosts and environments through mutations (1). Thus, the threats that coronaviruses pose are ever-changing and long term, and global health requires the quick characterization of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related proteins and systematic design of treatment and prevention options. Coronaviruses are characterized by the crown-like spike (S) glycoproteins on the surface of the virus particles (1). The coronavirus S protein is a member of the class I viral membrane fusion protein family present

Submitted December 23, 2020, and accepted for publication November 4, 2021.

*Correspondence: anna.tarakanova@uconn.edu

Editor: Tamar Schlick.

<https://doi.org/10.1016/j.bpj.2021.11.009>

© 2021 Biophysical Society.

in SARS, Middle East respiratory syndrome (MERS), influenza (1–3), human immunodeficiency virus (1,4), and Ebola (5) viruses. S proteins attach to cell-surface receptors, facilitating the viral membrane's fusion with the host membrane and entry of the viral capsid into the cell cytoplasm (1,6,7). The S protein is a trimeric structure with each monomer comprised of two functional subunits: the N-terminal S1 subunit responsible for binding to the host cell receptor and the C-terminal S2 subunit with machinery for fusion with the host cellular membrane (6,8–10). The critical first step in the fusion process occurs through the receptor-binding domain (RBD) on the N-terminal S1 domain of the S protein, which binds to the host cell receptor (8). The binding event is followed by proteolytic cleavage of the S protein by host proteases, resulting in significant conformational rearrangement of the S protein, shedding of the S1 domain, exposure of the S2 domain, and subsequent engagement of its fusion machinery, leading to host cell entry that leads to viral replication and cell death (11). The S protein is cleaved at the S1-S2 site between subunits and the proteolytic S2' cleavage site, activating the membrane fusion cascade (12–15). In the case of SARS-CoV-2, S proteins recognize and bind to the human ACE2 receptor, triggering the viral fusion and replication cascade and leading to the spread of COVID-19 (8).

The structural orientation and dynamic behavior of the RBD is critical for host cell receptor binding (11,14,16,17). The RBD is a metastable domain that fluctuates between open and closed states in the prefusion conformation (11,17). It commonly adopts a single-RBD-open conformation, but multi-RBD-open conformations have been observed upon receptor binding or in response to mutational design (16–19). The receptor-binding motif (RBM) is fully exposed and binds to cell-surface receptors to allow entry into the cell only in the open conformation of the RBD (20). Given that the RBD interaction with the ACE2 receptor is an essential viral mechanism, the S protein represents a prime target for immunogen design. Antibodies that block viral attachment and entry—neutralizing antibodies—bind almost exclusively to the RBD of the S protein (6,8,10). Although it may be possible that neutralizing antibodies bind to the S2 domain, the majority of studies show epitopes of neutralizing antibodies in S1 regions, mainly proximal to the RBD (10,19,21–23). Although the main mechanism for viral neutralization occurs through antibody blocking of the receptor-binding site, other mechanisms include prevention of ACE2 binding through steric clashes and inducement of conformational shifts that prevent binding (19,24–27).

In recent years, structural biology has been instrumental in vaccine development, and in particular, atomic-level control of immunogens via structure-based design is increasingly feasible (18,27). There are multiple challenges and considerations for the informed design of immunogenic S protein variants. Prior mutagenesis studies of MERS-CoV, SARS-CoV, and SARS-CoV-2 S protein variants demonstrated that stability of prefusion structure plays a key role

in viral fusion (14,16,18). A number of different mutations of the SARS-CoV-2 S protein have been designed in an effort to understand viral mechanisms and determine the best neutralizing variants. These include N-terminal domain (NTD) mutations (11,28), trimerization motif editing (11,14,17,26,28–30), proline mutations (16,18), and cleavage site mutations (11,16,29). Proline mutations in the S2 domain of the SARS-CoV-2 S protein, in particular, have been widely used for successful high-resolution cryo-electron microscopy (cryo-EM) structure determination and for generating structures with increased thermostability (16,18). Overall, evidence in the literature suggests the benefits of stabilizing mutations not only for prefusion state stabilization but also increased protein expression—both critical considerations for effective vaccine design. Although stabilization of the prefusion conformation has been successfully implemented through a structure-based design approach for MERS-CoV and SARS-CoV-2, there is as of yet no highly effective immunogen, although S proteins are being used to develop first-generation vaccine candidates at this time (31). However, further characterization is needed to elucidate viral and neutralizing antibody mechanisms for effective vaccine design (31). To that end, we developed dynamic models for a large subset of S proteins associated with SARS-CoV, MERS-CoV, and SARS-CoV-2 implemented through coarse-grained elastic network models and normal mode analysis (NMA). The use of NMA in protein science is a standard method for generating protein dynamics by calculating vibrational modes (15,32,33). This method is useful for investigating protein motions around an equilibrium starting structure (32,33), in which fluctuations obtained through NMA characterize a large fraction of the biologically accessible movements experienced by structured proteins and proteins that contain flexible regions (32,33). This is a well-accepted method for describing biologically relevant fluctuations of proteins, successfully applied to investigations of mechanically driven deformations, energy transport properties, studies of large molecular complexes, and ligand-gated ion channels (15,34–36). We apply these models to systematically analyze local protein domain dynamics of S protein systems, as well as their thermal stability, to characterize structural and dynamical variability among different variants.

Traditionally, protein domains are associated with conserved regions of protein sequence and building blocks of multimeric structures (37). However, protein evolution does not always discretize dynamics over these domains (23,27). Here, we consider rigid structural regions, termed dynamic domains, that behave in a quasi-independent manner around stabilized points, or hinges, and experience characteristic motion (17,38–41). The concretization of dynamic domains can highlight the functional roles of a localized area. For example, the RBD of the S protein is a qualitatively observed dynamic domain (11,16,17,42) whose fluctuation may provide a key viral mechanism for

immune evasion. The identification of dynamic domains can give a measure of protein stability by pinpointing regions that are mobile and unstable compared to less dynamic and more stabilized regions. Throughout, we refer to structural stability as a characterization of a protein structure that resists deformation and reorganization. There are few computational analysis methods directed toward this task. Existing software use Gaussian network model methods to construct coarse-grained models, which may result in segmentation and accuracy artifacts (40,41). Other methods rely on the use of machine learning predictors that are trained on a limited set of NMR structures (41,43). Overall shortcomings associated with existing methods are ease of use, robust capture of accurate dynamic motions, domain differences between homologous structures, and quality of training data. To overcome these limitations, we designed a new, to our knowledge, algorithm that is applicable to biological structures in general but is specifically developed for coronavirus S proteins.

We compare domain dynamics between SARS-CoV-2 mutants with SARS-CoV and MERS-CoV S proteins to establish the properties of various mutations and relate these to viral cellular fusion mechanisms. We then compare modeling results to available antibody binding and epitope data to create a SARS-CoV-2 antigenic map and offer predictions for targeted molecular design of effective immunogens. Overall, this framework can be applied to the analysis and comparison of viral S proteins and associated mutants to determine structural and dynamic artifacts of mutations, as well as to link S protein dynamics patterns to antibody binding, toward more effective, computationally driven immunogen design.

MATERIALS AND METHODS

Elastic network modeling and normal mode analysis

The use of NMA in protein science is a standard method for generating protein dynamics by calculating vibrational modes (34). This approach uses a harmonic potential to compute protein movements. Although this approach is not as robust as, for example, molecular dynamics simulation using a more complex protein potential, it is able to produce accurate, large-scale protein motions around a starting structure (32,33). Fluctuations obtained via NMA can explore a small radius of movements around the equilibrium position within a protein's free energy landscape (35). For structured proteins or those with flexible regions, this radius can characterize representative, biologically accessible protein motions (35). Indeed, studies show that the linear combination of low-frequency modes is adequate to characterize collective motions and intrinsically favored dynamic patterns of functional units of membrane proteins and large systems such as ion channels (32,36), receptors (32,44,45), and transporters (32,35,46). Additionally, other recent studies show that this is a valid method for describing realistic fluctuations of open and closed state S proteins, as well as for studying their nanomechanical properties (15,34).

In this study, anisotropic network models (ANMs) are constructed to coarse grain coronavirus S proteins. NMA is applied to ANMs to calculate vibrational normal modes and derive protein dynamics. ANMs are a variant

of elastic network models that coarse grain the protein structure on a per-residue basis to construct a mass and spring system to dramatically speed up the NMA calculations (our method takes ~10 min to execute for each S protein). It differs from the simplified one-dimensional Gaussian network model, as each bead is represented as three points rather than as a single point, thus accounting for directionality and generating a more robust and accurate set of motions (39,40,47). The ANM construction represents each α -carbon as a three-point vibrational node, reducing computational cost and loss of accuracy in comparison to explicitly modeling every atom on each multiatom amino acid (32,47). Our model implements connections between interacting nodes within a 15 Å cutoff distance. This includes interchain connections because the S protein is a multichain structure. If interprotomer nodes are within the cutoff distance, then a connection between them is represented by a spring. These same criteria are applied for intersubunit connections. Because the model construction is solely distance based, no additional springs or other refinements are included to account for or discriminate between specific intermolecular bonds (e.g., disulfide bonds). However, structural differences across variants that result from formation of new intermolecular bonds are reflected in the model construction. The node-spring composition for proteins is unique in the sense that mutation-driven structural change or Protein Data Bank (PDB) resolution can influence the network model (results of this artifact are discussed in [Effect of glycans and structural resolution on WT ANM dynamics](#)). When glycans are included in the PDB structures used for model construction, they are subject to the same modeling criteria.

We use the Python programming library ProDy (45) to construct ANM models along protein α -carbons, form associated Hessian matrices (topological description), and conduct NMA (diagonalization of the Hessian) in Cartesian space. Our approach ensures that at least 98% of the total system dynamic response is captured in a collective motion by first generating trajectories based on a linear combination of at least the first 15 normal modes weighted by their fractional variance (total contribution to motion). Trajectories are processed with MDTraj (48) and ProDy (45) programming libraries. All visualization is performed with visual molecular dynamics (VMD) with the aid of the Normal Mode Wizard extension (49). All trajectory videos are included in [Videos S1–S20](#).

Dynamic domain analysis and calculations

We employ dynamic domain analysis to characterize the specific cohesive, dynamic behavior of global domains in S protein systems considered here. Artifacts of a modal trajectory include vectoral and temporal data. Normal mode trajectories are parsed to find per-residue deformation vectors, deformation magnitude, coordinates of the starting structure, and coordinates of the deformed structure. The deformation data are obtained by comparing the starting structure to the most deformed structure in the normal mode trajectory. The most deformed structure is defined as the protein structure within the normal mode trajectory that has the highest root mean-square displacement (RMSD) compared to the original. Deformation profiles show per-residue distances found by comparing corresponding node positions between starting structure and most deformed structure:

$$D(a, b)_{\text{residue}} = \sqrt{\sum_i^{n=3} (a_i - b_i)^2}, i \in (X, Y, Z),$$

where a and b indicate a specific amino acid position and i indicates their components in X, Y, Z Cartesian space.

Deformation profiles are denoised to remove any outlier values that result from incomplete PDB structures. These data, in combination with starting structure coordinates, are used as input for a layered hierarchical agglomerative clustering algorithm that utilizes functions from the Scikit-learn programming library (50). Agglomerative clustering is the optimal choice because it avoids a specific cluster number constraint (unlike K-means or

spectral clustering) and thus does not limit the number of identified dynamic domains (51). Each pass of agglomerative clustering uses a different linkage criterion—Ward, complete, or single. These emphasize different properties to produce high-precision dynamic domain segmentation that can distinguish between small and large dynamical shifts while still respecting spatial barriers. The outputs of this analysis are locations of dynamic domains, local dynamics score (LDS), and global dynamics score (GDS). The LDS is the average deformation that occurs over all the nodes in an identified dynamic domain. The GDS is the average deformation experienced by the whole structure, or root mean-square displacement (RMSD). High GDSs typically correspond to structures that experience large global rocking motions. A dynamic domain is defined as an identified cluster whose average deformation, LDS, is higher than the GDS. LDSs that are lower and closer to the GDS indicate a dynamic domain that is more stable relative to the deformation experienced by the entire structure. There is no ceiling for LDSs. We note that a baseline for protein structural stability is measured by the GDS and the level of deviation from structural stability is measured by the difference in GDSs and LDSs.

We also calculate the percentage overlap between dynamic domain residues across S protein variants and identified antibody binding zones. Percentages are calculated with respect to dynamic domains and antibody binding zones by considering the number of common residues between the two groups. When finding the overlap with respect to dynamic domains, this number is scaled by the total number of residues within corresponding dynamic domains. When finding the overlap with respect to antibody binding zones, the number of common residues is scaled by the number of residues within the zones.

Sequence and structure analysis

One-to-one sequence comparisons are made using the BLAST Needleman-Wunsch Global Alignment software through the Blastp protein-protein webserver, in which the wild-type (WT) sequence is the subject sequence and the mutant is the query sequence (52). The BLAST tool gives an estimation of similarity between query and subject sequences. Multiple sequence alignment is performed on all presented sequences using the Clustal-Omega webserver on its default settings (53). The [Supporting materials and methods](#) contain the resulting multiple sequence alignment file and a description of all sequences used. Structural alignments and root mean-square deviation (RMSD) calculations are performed using the “super” tool within the PyMol alignment software suite (54). Cryo-EM docking of crystal structures inside maps is done using Chimera fit in map functionality (55). Solvent-accessible surface area (SASA) is computed using the Shrake-Rupley SASA function from the MDTraj programming library (48). Salt bridges are measured within a 3.2 cutoff radius (56,57) using the software VMD (49). In-house Python scripts are used in all structural analysis.

Thermal stability prediction

Thermal stability is the ability of biological materials to resist degradation due to heat, pH change, and time evolution. It can be a determining factor for vaccine viability and is therefore critical for experimental vaccine design. The Gibbs unfolding free energy (ΔG J/mol), and the difference between WT and mutant ($\Delta\Delta G$ J/mol), is considered as a measure for protein thermal stability. Here, we create a thermal stability predictor to calculate $\Delta\Delta G$ and ΔG for protein sequences upon mutation as a measure of thermal stability. Existing computational methods for measurement of thermal stability rely on protein sequence or structure information and utilize machine learning or deep learning methods such as support vector machine (58) or neural networks (39,59,60). We introduce a novel, to our knowledge, joint sequence- and structure-based thermal stability predictor to calculate single structure free energy and free energy change upon mutation. Although both PDB structures and sequences are used in the training

process, in which PDB structures are used to derive many of the training features (see [Table S3](#)), only the sequence is required for user input. So, our predictor returns the same outputs for both complete and incomplete PDB structures.

For training, we first employ a novel, to our knowledge, sequence embedding technique where embedding vectors are calculated with two different embedding approaches: sequence graph transform (61) and bidirectional LSTM models (60). Then, the total features are parsed through a convolutional neural network model. The predictor is trained on long short-term memory (LSTM) combined biochemical features, biological features, structural properties, and energy terms (see [Table S3](#)) that were extracted for each entry in our data set. We use a combined data set for training that includes the ProTherm data set (62) and PoPMuSiC data set (63), containing 1) the PDB structure of the WT protein, 2) mutation details such as location and residue type, 3) temperature, 4) pH, and 5) Gibbs free energy change upon mutation. Our convolutional neural network model includes hyperparameter tuning to increase performance and prediction accuracy. The optimal performance is found when hyperparameters including number of epochs, batch size, and learning rate are tuned. We found that 128 neurons per fully connected convolution layer and a 50% dropout rate prevent overfitting while still predicting optimal results. The total data set consists of 16,847 mutation points for 836 proteins after removing redundancies. For testing, we use the independent I-mutant data set (64). Our model also includes hyperparameters to tune the data and increase prediction accuracy. The close proximity of values in our binary output indicates that our predictor is well-trained and captures the most possible features from thermally stable and unstable classes. Importantly, we see no bias in contrast to other predictors. The 10-fold cross-validation method is used to predict $\Delta\Delta G$ -values and their associated standard error. The Python libraries Keras (65), TensorFlow (59), and Pandas (66) were used for algorithm construction and implementation.

RESULTS AND DISCUSSION

Elastic network model dynamics qualitatively reflect cryo-EM data

We compare ANM models for S proteins and their corresponding NMA motions to true structures and their cryo-EM maps. Note that [Table 1](#) provides a description of all mutant SARS-CoV-2 PDB structures described in the following studies. The results from our analysis show that SARS-CoV-2 S protein models effectively capture the metastable nature of the RBD reflected in associated cryo-EM maps ([Fig. 1](#)). Among available SARS-CoV-2 S protein structures, we consider two RBD-closed structures SC2.S1.TM1 (PDB: 6VXX) and u1S2q (PDB: 6X2C); three one-RBD-up structures BiPro (PDB: 6VSB), SC2.S1.TM1 (PDB: 6VYB), and u1S2q (PDB: 6X2A); and a single two-RBD-up structure u1S2q (PDB: 6X2B).

First, ANM models based on BiPro (16) and SC2.S1.TM1 (8) are constructed using one-RBD-up starting structures to compare the match between one-RBD-up model trajectories (from one-RBD-up state to closed state) to corresponding cryo-EM maps. Qualitatively, the modal trajectory obtained from the BiPro ANM (see [Video S3](#)) experiences the same characteristic hinge-like movements of the RBD between open and closed conformations identified in videos obtained by experimental cryo-EM studies on the BiPro sequence (42). SC2.S1.TM1 ANM dynamics similarly reflect the

TABLE 1 PDB structures used as input to ANM models in this study

| Mutant name | PDB | Reference | Sequence length | Percent unresolved | WT similarity | Conformation | Expression level | Mutation description | Thermal stability ($\Delta\Delta G$ J/mol) |
|------------------|-----------|-----------|-----------------|--------------------|---------------|---|---|---|---|
| SC2.S2.TM1-1 | 6ZGG | (28) | 1287 | 17% | 93% | one RBD up | closed (34%), intermediate, (39%), open (27%) | signal peptide, 2P, trimerization motif | 1.09 \pm 0.17 |
| BiPro-1 | 6Z97 | (67) | 1273 | 22.9% | 94% | one RBD up | unknown | 2P, GSAS furin cleavage, trimerization motif | 0.88 \pm 0.10 |
| BiPro | 6VSB | (16) | 1288 | 25.4% | 94% | one RBD up | unknown | 2P, GSAS furin cleavage, trimerization motif | 0.93 \pm 0.19 |
| SC2.S1.TM1 | 6VXX/6VYB | (8) | 1281 | 24.5% | 93% | all RBDs down (6VXX) or one RBD up (6VYB) | unknown | signal peptide, 2P, GAGS furin cleavage, trimerization motif | 0.94 \pm 0.02 |
| HexaPro | 6XKL | (18) | 1288 | 24.7% | 94% | one RBD up | unknown | 6P, GSAS furin cleavage, trimerization motif | 1.21 \pm 0.10 |
| SC2.N1.C1.2P.TM2 | 6XF6 | (68) | 1266 | 24.2% | 94% | one RBD up | unknown | NTD clip, 2P, GSAS furin cleavage, trimerization motif | 0.99 \pm 0.11 |
| u1S2q | 6X2B | (17) | 1273 | 24.6% | 93% | all RBDs down (6X2C), one RBD up (6X2A), two RBDs up (6X2B) | open 67% | 2P, GSAS furin cleavage, trimerization motif, A570L T572I, F855Y, N856I | 0.32 \pm 0.11 |
| SC2.C2.1P.TM3 | 7AD1 | (29) | 1297 | 26.5% | 93% | one RBD up | closed (42%), intermediate (38%), open form (20%) | SRAG furin cleavage, 3P, trimerization motif | 0.82 \pm 0.14 |
| SC2.C1.2P.TM4 | 6XM0 | (69) | 1288 | 18.7% | 93% | one RBD up | unknown | NTD clip, 2P, GSAS furin cleavage, trimerization motif | 0.71 \pm 0.09 |
| SC2. TM4-1 | 6XR8 | (12) | 1310 | Unknown | 97% | all RBDs down | unknown | extended trimerization motif | 0.55 \pm 0.11 |
| SC2.C1.2P | 7CN9 | (70) | 1127 | 13% | 88% | one RBD up | unknown | NTD clip, 2P, GSAS furin cleavage, trimerization motif | 0.41 \pm 0.02 |
| SC2.C1.TM4-2 | 7KDH | (71) | 1288 | 25.5% | 94% | one RBD up | unknown | GSAS furin cleavage, trimerization motif | 0.93 \pm 0.14 |
| BiPro-0 | 6ZP7 | (42) | 1273 | 22.7% | 99.7% | one RBD up | unknown | 2P | 1.10 \pm 0.09 |

Thermal stability ($\Delta\Delta G$) values are measured in comparison to WT thermal stability of $\Delta G = 0.47$ J/mol. Higher $\Delta\Delta G$ -value denotes higher thermal stability. Thermal stability values less than 0.60 are considered to have a milder thermal stability improvement. Thermal stability values between 0.6 and 0.9 are considered to have moderate improvement. Thermal stability values greater than 0.9 are considered to have a significant improvement. Sequence length, percent of atomic coordinates unresolved within the PDB, and the similarity of each sequence to the WT sequence are presented. The [Supporting materials and methods](#) contain additional sequence details. Note that furin cleavage mutations occur at the S1-S2 junction site.




FIGURE 1 (A) 6VYB (8) starting structure inside its own cryo-EM map. (B) NMA-derived 6VYB closed structure aligned inside 6VXX (8) cryo-EM map. (C) Path trace of 6VYB ANM modal trajectory with vectors indicating direction and degree of displacement. (H) SARS-CoV-2 sequence map showing protein domains as well as S1/S2 and S2' cleavage sites and start point of trimerization motif (TM). (D) The 6X2B (17) two-RBD-up starting structure inside its cryo-EM map. (E) NMA-derived 6X2B one-RBD-up structure aligned inside 6X2B (17) cryo-EM map. (F) NMA-derived 6X2B closed structure aligned inside 6X2A (17) cryo-EM map. (G) Path trace of 6X2B ANM modal trajectory with vectors indicating direction and degree of displacement. Extra space between crystal structure and map can be attributed to the removal of surface glycans and/or regions of missing atomic structure. Proteins in (A–G) are colored according to the sequence map. NTD, N-terminal domain; RBD, receptor binding domain; RBM, receptor binding motif; CTD, C-terminal domain; TM, trimerization motif of transmembrane domain. To see this figure in color, go online.

transitions between open (Fig. 1 A) and closed (Fig. 1 B) cryo-EM-identified states (8) (see Video S4). Fig. 1 A shows the alignment of the SC2.S1.TM1 structure (PDB: 6VYB) to its cryo-EM map. The closed RBD structure of SC2.S1.TM1 (PDB: 6VYB) resulting from NMA is aligned inside the closed SC2.S1.TM1 (PDB: 6VXX) cryo-EM map (Fig. 1 B) to determine how well NMA can reproduce experimentally identified states. The RMSD between the closed 6VYB model and the closed 6VXX structure is 1.42 Å, and 87.2% of the atoms in the closed 6VYB model fall within the 6VXX structural contour, as measured by Chimera fit in map function, establishing that open SC2.S1.TM1 structures can accurately capture large-scale S protein movements.

Next, we compare the match between two-RBD-up model trajectories and dynamic domain analysis results of u1s2q (from the two-RBD-up state to the one-RBD-up state to the closed state) to corresponding cryo-EM maps. Cryo-EM analysis of the u1s2q S protein reveals a two-RBD-up state (PDB: 6X2B), one-RBD-up state (PDB: 6X2A), and all RBDs closed state (PDB: 6X2C) (17). The propensity to adopt a two-RBD-up position is likely due to its unique set of A570L, T572I, F855Y, and N856I mutations (17). First, an ANM of the two-RBD-up u1s2q protein, 6X2B, was constructed and NMA was performed on the model to capture its dynamics. Frames that exhibit conformations that were the closest aligned with the one-RBD-up (PDB: 6X2A) and closed (PDB: 6X2C) crystal structures were extracted. The extracted conformations found via NMA were aligned with the crystal structures and their cryo-EM maps (Fig. 1, E–G). The RMSD between the one-RBD-up model of u1s2q (PDB: 6X2B) and one-RBD-up crystal

structure (PDB: 6X2A) is 0.66 Å and 89.4% alignment with the 6X2A map. The RMSD between the closed model of u1s2q (PDB: 6X2B) and 6X2A is 0.72 Å and 85.9% aligned with the 6X2C map. In the NMA video of 6X2B (see Video S5), the up RBDs are seen to fluctuate separately; one highly flexible RBD (LDS = 1.51) closes while the other, less flexible RBD (LDS = 0.83) flips upward (Fig. 3 C). There is an intermediate state when both are in a mostly closed state. In this instance, the NMA method does not completely reproduce a down structure from the two-RBD-up structure. Overall, however, experimental studies show that the NTD and RBD domains undergo significant conformational change and exhibit flexibility, supporting the dynamic fluctuation observed in the dynamic network models (17).

Effect of glycans and structural resolution on WT ANM dynamics

All available experimental structures of SARS-CoV-2 S proteins contain unresolved structural regions. To verify that the ANMs and NMA yield consistent characteristic motions, we consider the computationally refined WT S protein structure generated by Amaro et al. (72). This structure is only missing data for the first 13 residues—the most resolved and accurate WT structure at the time of this study (72). NMA analysis and dynamic domain analysis is performed on a set of systematically reduced WT ANM models containing 1) intact glycans surrounding the protein, 2) removed glycans, 3) removed S2 subunit after residue 1146, and 4) removed commonly unresolved regions 1–26, 67–81, 144–187, 243–262, 621–640, 672–689, 828–850, and 1146–1273. Please see the

Supporting materials and methods for a full breakdown of missing regions for all PDB structures considered in this study. We verify that this WT structure is able to capture dynamical movements presented in other PDB snapshots.

First, NMA is conducted on the WT model that includes glycans surrounding the protein. The glycans exhibit independent, localized dynamic behavior, whereas the protein's mobility is significantly damped relative to the reduced structures (i.e., without glycans) (Fig. 2 A). When the WT structure is analyzed without the glycans, the general pattern of dynamics is preserved, as shown by deformation and solvent-accessibility measurements (Fig. 2 B). The dynamics are more pronounced and less damped, capturing more subtle local dynamics in the S2 subunit that would otherwise go undetected. Thus, glycan removal for NMA analysis can provide a more detailed breakdown of functional mechanisms. Additionally, glycosylation sites may differ from protein to protein, so characterization of S protein dynamics without the presence of glycans can yield baseline motions that are consistent independent of glycosylation patterns (73). Still, including glycans in dynamics analysis may be

useful to help identify the function of the glycans in different locations. For example, the glycans surrounding the location of the up RBD (Fig. 2 A, red) are predicted to be the most dynamic from NMA. Glycan studies by Amaro et al. note that glycans that surround the up RBD help stabilize it in the open conformation through hydrogen bonding (72). The high glycan flexibility exhibited in the models may provide further mechanisms for RBD stabilization. We also note that our analysis predicts dynamic domains within the extended region of the S2 subunit trimerization motif (Fig. 2, A and B). However, under biological conditions, these are partially locked or stabilized within the virion membrane surface (1). Because of the geometry of the trimerization motif, a protruding structure that covers a large surface area, the NMA may bias toward predicting dynamics within this region rather than adjacent regions including the RBD. Thus, here we consider available PDB structures with unresolved trimerization motifs to evaluate realistic motions of RBD-adjacent domains.

We next consider the WT protein elastic network model with residues 1146–1273 removed and the WT elastic




FIGURE 2 The evolution of NMA results and dynamic domain results for WT SARS-CoV-2 S protein models (72) with consecutive segments removed. The progression starts with (A *i*) WT model with fully resolved trimerization motif and glycans, (B *i*) removed glycans, (C *i*) removed extended commonly unresolved S2 residues 1146–1273, and (D *i*) removed additional commonly unresolved regions: 1–26, 67–81, 144–187, 243–262, 621–640, 672–689, and 828–850. Each model is accompanied by local dynamics scores (LDSs) in the legend in the upper right corner of per-residue deformation plots (*ii*) and solvent-accessibility change plots (*iii*) to assess changes in protein movement calculations. (A) is rotated to highlight all represented dynamic domains. The average distances traveled by the RBD oscillation are 3.84 and 3.50 Å for (C) and (D), respectively. To see this figure in color, go online.

network model with other common unresolved regions removed (Fig. 2, C and D). The deformation and solvent-accessibility profiles suggest that these reduced models exhibit similar patterns of oscillation that are more consistent with what is seen experimentally for other S proteins with the corresponding resolved regions. Dynamic domains are predicted around the location of WT S protein RBDs, where RBD oscillation typically occurs (8,14). In the WT model missing residues 1146–1273, the RBD moves a distance of 3.84 Å when alternating between open and closed states. The WT model missing both residues 1146–1273 and other commonly unresolved regions corresponds to a 3.5 Å displacement of the RBD. It also appears that removal of the NTD structure from positions 1–262 (approximately) encourages higher associated protein deformation. Additionally, removal of residues is hypothesized to accentuate weak regions and increase dynamic domain segmentation. This is also the case when we compared the dynamics results of BiPro and BiPro-1 mutant structures (see [Dynamics of S protein mutants and associated thermal stability predictions inform experimental observations](#)). This suggests that protein resolution levels can alter ANM-predicted dynamical patterns, although not dramatically. However, by confirming ANM dynamics with experimental data, even incomplete structures from cryo-EM may provide additional insights into S protein mechanisms.

Dynamics of S protein mutants and associated thermal stability predictions inform experimental observations

This section presents the dynamic domain patterns associated with different S protein mutants to compare with and confirm experimental findings, thereby further validating our approach. We also present the thermal stability results and discuss their implications. In the next section, [Mutations in SARS-CoV-2 S protein sequence induce variability in protein dynamics](#), we explicitly synthesize this information to cluster families of mutations and to draw conclusions about their effect on dynamics and thermal stability, and the associated functional significance. We build ANMs for SARS-CoV-2 mutants BiPro (16), SC2.S1.TM1 (open RBD, PDB: 6VYB) (8), HexaPro (18), SC2.S1.TM1 (closed RBD, PDB: 6VXX) (8), SC2.C2.1P.TM3 (29), SC2.N1.C1.2P.TM2 (68), BiPro-1 (67), SC2.C1.2P (70), SC2.C1.TM4-2 (71), SC2.TM4-1 (12), BiPro-0 (42), u1S2q (17), and SC2.C1.2P.TM4 (69) to first verify their agreement with experimental results and to gain insight into their associated immunogenic and mutation-related properties. These structures represent a comprehensive list of experimentally studied one-RBD-up S protein prefusion structures and one consensus model (Table 1). We consider primarily RBD-up configurations as starting equilibrium structures for building network models because these can effectively sample both open (RBD-up) and closed (RBD-

down) conformations. Dynamic analysis of closed structures such as 6XR8 (Fig. 5B) did not produce RBD-up conformations but explored bending and twisting motions experienced in the closed state (see [Video S10](#)). Generally, in our analysis, models that contain significant region(s) of deformation include dominant and auxiliary dynamic domains. Highly stable structures may only contain auxiliary domains, and LDSs do not differ significantly from the GDS. In addition to identifying the location of dynamic domains on three-dimensional S protein structures, we also present these domains on protein deformation and solvent-accessibility plots to quantify patterns in protein dynamics (Figs. 3, 4, and 5). Dynamic domains typically correspond to regions that exhibit high deformation or solvent accessibility as compared to the rest of the structure. Finally, to complement our dynamic models, we evaluate the effects of mutations on the thermal stability of each sequence through our novel, to our knowledge, thermal stability predictor (Table 1).

Analysis of the BiPro ANM trajectory (Fig. 3 A) shows a dominant dynamic domain surrounding the up RBD with auxiliary domains around the NTD and an additional down RBD. Experimental studies confirm that thermal stability displayed by the BiPro RBD promotes an unstable three-RBD-up conformation upon binding to the ACE2 receptor (16). In our analysis, the range of thermal stability across all mutants is $\Delta\Delta G = [0.32 \text{ J/mol}, 1.21 \text{ J/mol}]$. The thermal stability increase of BiPro compared with the WT protein, at $\Delta\Delta G = 0.93 \text{ j/mol}$, represents a significant increase in thermal stability, correlating well with experimental observations. Our analysis shows that dynamic domains cover significant surface area in the S1 subunit. Their flexibility predicts the reorganization to the three-RBD-up structure. However, there is large variability among the local domain dynamics in the S1 subunit, ranging from stable regions ($LDS = GDS = 1.05$) to highly unstable, dynamic regions ($LDS = 2.9$). The heterogeneity in dynamic behavior may contribute to the transience of the multi-RBD-up configuration. Additionally, experimental flexibility analyses show that the resolution propensity of the S1 domains is decreased compared with the rest of the structure (16,42). The 6VSB ANM dynamic domain pattern confirms the mobility of these regions.

Next, we analyze BiPro-1 (PDB: 6ZP7) to further emphasize the contribution of protein resolution to observed dynamics. Both BiPro and BiPro-1 mutants contain the same family of mutations and have a sequence alignment of 99.8% to each other (Table 1; sequences are available in the [Supporting materials and methods](#)). Overall, we found that both proteins experience the same deformation range, contain a dynamic domain around the up RBD, and contain an auxiliary domain adjacent to a more dominant domain (see Fig. 2, A and B). However, BiPro contains additional dynamic domains in the S1 subunit. This discrepancy may be due to the structural changes caused by differing




FIGURE 3 The domain dynamics associated with (A *i*) BiPro (16), (B *i*) BiPro-1 (67), (C *i*) u1S2q (17), and (D *i*) HexaPro (18) ANMs. The PDB, global dynamics score (GDS), LDSs, deformation profile (*ii*), and Δ SASA profile (*iii*) are listed for each structure. On each three-dimensional (3D) structure and profile, identified dynamic domains are labeled in different colors, and their LDSs are listed in each legend. On the profiles, the location of dynamic domains may look segmented, but these are often located in the same 3D space. Dynamic domains are classified as regions that experience similar levels of deformation but can also capture a small number of residues that are adjacent to dynamic regions and experience deformation in the same direction. Alternatively, residues that experience similar levels of deformation might be split into different dynamic domains because they are located in different regions of coordinate space or fluctuate in different directions. Associated dynamic videos are included in the [Supporting material](#). To see this figure in color, go online.

trimerization motif sequences, but more likely, it is due to their differing levels of structural resolution (Table 1). The BiPro PDB structure contains missing regions in positions 330–334, 444–490, and 501–502, whereas BiPro-1 PDB does not (16,67). This further confirms that mutation-caused structural shifts and protein resolution levels can alter elastic network model construction and thus predicted dynamics or protein stability, making experimental validation essential to NMA-derived dynamics. By confirming domain dynamics with experimental data, NMA can provide additional insight on incomplete crystal structures.

Local domain dynamics of the HexaPro (18)-based model (Fig. 3 D) are similar to BiPro. Considering that the sequences are similar (the BiPro sequence is mutated with four prolines in the S2 subunit to create HexaPro), it is expected that their associated dynamics would be similar. We discuss effects of proline mutations further in [Mutations in SARS-CoV-2 S protein sequence induce variability in protein dynamics](#). The BiPro model does result in a dynamic

domain around the RBD, whereas this is not the case in the HexaPro model. HexaPro shows a single dynamic domain surrounding the RBD and adjacent S1 regions. These dynamics are confirmed by cryo-EM studies that suggest that the S1 subunit is further secured (18). The HexaPro sequence also has the highest predicted thermal stability of the SARS-CoV-2 S proteins studied, $\Delta\Delta G = 1.21$ J/mol. Experimental thermal stability assessments show that the A942P mutation, not included in BiPro, was particularly powerful in increasing thermal stability (18).

The SC2.C1.TM4-2 (PDB: 7KDH) (71) sequence contains GSAS in the furin cleavage site and trimerization motif mutations and is missing proline mutations compared to the structures discussed thus far, although it is predicted to have higher thermal stability ($\Delta\Delta G = 0.93$ J/mol). Dynamics analysis of the ANM trajectory shows a dynamic domain extending into the S2 subunit (Fig. 4 D). Aside from this difference, the S1 subunit local domain dynamics resemble BiPro most closely. Experimentally, the RBD experiences




FIGURE 4 The domain dynamics associated with (A *i*) SC2.C2.1P.TM3 (29), (B *i*) SC2.S2.TM1-1 (74), (C *i*) BiPro-0 (42), (D *i*) SC2.C2.TM4-1 (12), (E *i*) SC2.C1.2P (70), (F *i*) SC2.N1.C1.2P.TM2 (68), (G *i*) SC2.C1.2P.TM4 (69), and (H *i*) SC2.S1.TM1 (8) ANMs. The analysis results for the open-RBD structure of SC2.S1.TM1, 6VYB, are shown in (H) and the closed structure in Fig. 5 A. The PDB, GDS, LDSs, deformation profile (ii), and Δ SASA profile (iii) are listed for each structure. Dynamic domains are color coded on 3D structures according to LDS. Associated dynamic videos are included in the [Supporting material](#). To see this figure in color, go online.

increased rigid body movement and the surrounding NTD regions experience smaller shifts (71); this is consistent with our identified dynamic domain locations and LDS values. The RBD has a high LDS of 1.73, relative to its GDS of 1.16, and the surrounding NTDs are identified as dynamic domains that have LDSs of 1.58 and 1.19.

The SC2.S1.TM1 (8) sequence contains the most diverse set of mutations associated with RBD-up structures in this study (Fig. 4 H; Table 1), containing a signal peptide, 2P, GAGS in the furin cleavage site, and trimerization motif mutations. Notably, the ANM of open SC2.S1.TM1 (corresponding to PDB: 6VYB) produces a lower number of dynamic domains than many of the other structures explored. These cover a smaller surface area; one is located around the up RBD and its adjacent NTD, and the other covers one of the down RBDs. The up RBD is the dominant

domain and displays the highest level of instability (LDS = 2.21). The auxiliary domain around the down RBD is only slightly unstable, meaning that there is a small difference between the LDS (1.05) and GDS (0.91). Together, these results indicate that that structure is mostly stable. Walls et al. note that the SC2.S1.TM1 S protein not only adopts one-RBD-up and down conformations but does not display a propensity to reorganize into multi-RBD-up structures upon binding (8). Cryo-EM identified structures demonstrate that the closed RBDs lock down more firmly than in structures like BiPro (8); this is consistent with our observations from the dynamic domain analysis. The majority of the S1 subunit structure is stable, and the dominant dynamic domain switches between the experimentally observed open and closed states. Because the majority of S1 regions are located in dynamically stable zones, they may not easily




FIGURE 5 The domain dynamics associated with the ANMs of closed structure SC2.S1.TM1 (8) (A *i*) and SC2.TM4-1 (12) (B *i*). The PDB, GDS, LDSs, deformation profile (*ii*), and Δ SASA profile (*iii*) are listed for each structure. Dynamic domains are color coded on 3D structures according to LDS. Associated dynamic videos are included in the [Supporting material](#). To see this figure in color, go online.

reorganize like the RBDs of the BiPro and HexaPro structures. Additionally, SC2.S1.TM1 is predicted to have moderate thermal stability ($\Delta\Delta G = 0.94$) compared with the WT, which is only slightly greater than the BiPro sequence ($\Delta\Delta G = 0.93$) that does not contain the signal peptide mutation.

Like SC2.S1.TM1, the SC2.S2.TM1-1 (PDB: 6ZGG) sequence also contains a signal peptide, 2P, and trimerization motif (28). Unlike SC2.S1.TM1, it does not contain the furin cleavage mutation, and its modal trajectory produces different domain dynamics (Fig. 4 *B*). In SC2.S2.TM1-1, there are larger dynamic domains within the S1 subunits, especially around the RBD, as well as dynamic domains around the S1-S2 junction that extend into both S1 and S2 subunits. This is in contrast to SC2.S1.TM1, which presents smaller and more restricted domains only in the S1 subunit. Given that SC2.S1.TM1 contains the furin cleavage mutation and SC2.S2.TM1-1 does not, it may be the cause of these downstream dynamic changes. In fact, prior studies on SC2.S2.TM1-1 suggest that the absence of the GAGS furin cleavage mutation promotes disorder between the S domains and lowers thermal stability (8,75). However, we predict that its thermal stability, $\Delta\Delta G = 1.09$, is increased in comparison to SC2.S1.TM1, $\Delta\Delta G = 0.94$, which contains the same family of mutations plus the GAGS furin cleavage mutation. In comparison to the WT protein, which is also missing the furin cleavage mutation, SC2.S2.TM1-1 does indeed display an increased thermal stability. The experimental study also notes the structure is able to sample open, closed, and intermediate

states with similar frequency (28). The domain dynamics analysis also supports this observation; the RBD-adjacent S1 domains are unstable (exhibiting a dynamic domain) and may modulate intermediate states.

Like the BiPro and SC2.S1.TM1 sequences, the SC2.N1.C1.2P.TM2 (PDB: 6XF6) (68) sequence contains a GSAS furin cleavage mutation, 2P, and trimerization motif mutations (Table 1). Unlike these other sequences, it contains an NTD clip mutation. ANM dynamics analysis of the SC2.N1.C1.2P.TM2 model (Fig. 4 *F*) shows a decreased number of dynamic domains that cover less surface area. Like the other sequences, it contains a highly dynamic up RBD and an auxiliary dynamic domain. This auxiliary (*red*) domain, however, is located in the S2 domain. We suspect that the different sequence architecture of the NTD causes structural artifacts and changes in auxiliary domain location. Unfortunately, the corresponding experimental study to SC2.N1.C1.2P.TM2 was not yet published at the time of this research, and thus, these observations are not available for additional insights. Our thermal stability predictions show a moderately high improvement over the WT ($\Delta\Delta G = 0.99$ J/mol). Interestingly, this value is higher than that of BiPro ($\Delta\Delta G = 0.93$ J/mol), which contains the same family of mutations except for the NTD clip. Their trimerization motif substitutions differ. Thus, the NTD mutation and/or trimerization motif mutation may increase thermal stability in this case.

Unlike most of the other sequences considered here, SC2.C2.1P.TM3 (PDB: 7AD1) possesses an SRAG furin

cleavage mutation as opposed to the more commonly used GSAS mutation (29). From the domain dynamics (see Fig. 4 A), the SRAG mutation in combination with three proline mutations provides an S2 stabilizing effect because there are no independent dynamic domains located in the S2 subunit. The addition of the proline mutation may also enhance the stabilization provided by SRAG. The corresponding experimental study notes that the mutations in the SC2.C2.1P.TM3 structure resulted in open, closed, and intermediate states with slightly more preference toward closed structures (29). This is supported by our dynamics analysis, which predicts that most of the S1 subunit domains are stabilized (Fig. 4 A). Experimental thermal stability analysis shows that the collective mutations performed on SC2.C2.1P.TM3 increase protein thermal stability, and the trimerization motif mutation in position 614 contributes greatly toward protein fusogenicity (29). Likewise, our results predict that these mutations moderately improve thermal stability, $\Delta\Delta G = 0.82$ J/mol, as compared to the rest of the mutants.

The BiPro-0 (PDB: 6ZP7) (Fig. 4 C) sequence is the most similar to the WT and only contains the 2P mutation (42). We note that the structure was produced by consensus computational modeling rather than experimental methods or molecular dynamics (42). Dynamics analysis identifies dynamic domains in the S1 subunit, the dominant domain being the RBD and the auxiliary domain covering the adjacent RBD and NTD. Interestingly, dynamic domains are not identified in the S2 subunit despite the limited number of mutations and no missing structural regions. This may be attributed to its mutations or, perhaps, to an artifact of the computational modeling that caused some structural change. In a separate study, the principal component analysis of BiPro-0 structure showed that the NTD and RBD both fluctuate together, but the RBD shows a much more complex movement pattern (42). This further confirms our analysis, which predicts the RBD to have a higher degree of movement (LDS = 1.89) than the auxiliary domain (LDS = 0.6). Thermal stability predictions show BiPro-0 to have very high thermal stability ($\Delta\Delta G = 1.10$), possibly demonstrating the power of coupled proline mutations.

Lastly, we note the effect of the trimerization motif in PDB structures and resulting dynamic domain output. All of the structures listed in Table 1 have large unresolved portions in the trimerization motifs; however, the SC2.TM4-1 closed structure, 6XR8 (12), has ~60 additional amino acids resolved in the trimerization motif compared to most structures. When comparing the SC2.TM4-1 (Fig. 5 B) ANM dynamics to another closed structure, 6VXX (Fig. 5 A), the general deformation trend and dynamic domain signature look similar with the exception of the trimerization motif region. However, the overall level of deformation is increased for SC2.TM4-1 (GDS = 0.92) compared with SC2.TM4-1 (GDS = 0.26). In synthesis with the structural resolution insights gained from the WT structure, this result points to

partially resolved trimerization regions contributing to more pronounced global dynamics and fully extended, resolved trimerization motifs damping S protein global dynamics. Overall, we find that there are specific dynamic signatures associated with each presented S protein mutant. Both predicted dynamics and thermal stability predictions closely agree with experimental observations. These results provide the motivation and points of comparison to understand the effect of each family of mutations: proline mutation, NTD editing, and furin cleavage editing.

Mutations in SARS-CoV-2 S protein sequence induce variability in protein dynamics

The patterns in dynamic signatures computed for the presented protein mutant models suggest that there may be specific protein behaviors associated with each family of mutations. Therefore, we first compared the dynamical differences between S protein models associated with certain mutations to form an initial set of hypotheses to investigate. Then, because different structures contain unique sets of unresolved regions, we create artificial control(s) in which the aggregates of all unresolved regions within the structures being compared are removed. Lastly, we introduce a series of case studies (Supporting materials and methods, Section 9) to resolve whether ANM model differences emerge from changes to sequence and subsequent alteration to structure or are artifacts of model sensitivity to structural alteration through, e.g., specific refinement protocols used by the experimental labs. The case studies provide a baseline that suggests that all measured dynamical differences between mutant proteins and their controls are likely due to structural deviations driven primarily by protein sequence changes.

Effects of the furin cleavage mutation

The presence of the furin cleavage mutation at the S1/S2 subunit is common among all S protein mutants surveyed in the literature. Our analysis shows that this mutation may have an effect on S protein dynamic patterns, structural stability, and thermal stability. A key motivation for additional analysis of these mechanisms stems from common patterns in the presented S protein mutants and their associated dynamics. We first consider all proteins that sample both open and closed conformations, all of which contain furin cleavage mutations (see Table 1) at the S1-S2 subunit junction except SC2.S2.TM1-1, BiPro-0, and the WT sequence. The remaining structures have SRAG (SC2.C1.2P.TM4), GAGS (SC2.S1.TM1), or GSAS—the most common furin cleavage mutation. We do not include BiPro-0 in this analysis considering that the structure was resolved by consensus modeling, which may affect its structure and corresponding dynamics. Interestingly, the WT and SC2.S2.TM1-1 structures do not contain the furin cleavage mutation and present dynamic domains in the S2 subunit. This motivates the hypothesis that RBD fluctuations transmit forces to

the rest of the structure, including the S2 subunit. Stabilizing furin cleavage mutations can secure the S1-S2 junction, redistributing forces to S1 subunit regions to create a more stable S2 subunit. In the absence of the furin cleavage mutation, the S2 subunit may act as a shock absorber by presenting dynamic domains. For example, SC2.S2.TM1-1 lacks a furin cleavage mutation and has lower LDSs in the S1 domain, closer to the GDS, than structures whose dynamic domains are restricted to the S1 subunit. Most S proteins exhibit LDSs in dominant dynamic domains that are at least 0.70 greater than their GDSs, whereas the dominant dynamic domain in SC2.S2.TM1-1 displays an LDS that is lower. In fact, SC2.C2.TM3, BiPro-0, BiPro, SC2.C1.2P.TM4, and SC2.S1.TM1 all exhibit dominant dynamic domains with LDSs exceeding GDS by at least 1.30. This suggests that the additional S2 subunit dynamic domains absorb some of the force that is transmitted to S1 subunit domains, thereby reducing the level of deformation exhibited by S1 dynamic domains. This hypothesis is strengthened by experimental observations that note furin cleavage mutations can control RBD allosteric effects through S2 domain changes (71). We note that although other models, including SC2.C1.TM4-2 and SC2.N1.C1.2P.TM2, present dynamic domains in their S2 subunits, this behavior may be attributed to multiple factors, such as the NTD clip mutations and higher levels of unresolved structure.

To further understand the possible implications of having a furin cleavage mutation, we first compare the structure and dynamics of SC2.S2.TM1-1 (PDB: 6ZGG) with SC2.S1.TM1 (PDB: 6VYB). The SC2.S2.TM1-1 sequence contains the same family of mutations as the SC2.S1.TM1 sequence, minus the furin cleavage mutation. There is a large difference in the number of unresolved regions between the two structures, 7.5% higher in SC2.S1.TM1 (Table 1). To characterize the effect of unresolved regions, the common unresolved regions between SC2.S2.TM1-1 and SC2.S1.TM1 (for which there is overlap; see breakdown in Supporting materials and methods, Section 7) are removed from SC2.S2.TM1-1 to create control SC2.S2.TM1-1' (Fig. S1 A). SC2.S2.TM1-1' exhibits dynamic domains around the furin cleavage sites in the lower S1 regions and upper S2 regions similar to SC2.S2.TM1-1, but dynamics are damped in other regions of the S2 subunit. Although SC2.S2.TM1-1 and its control display some differences in their dynamic patterns, there are apparent commonalities when compared to SC2.S1.TM1. Both present increased dynamic domains in the S1 subunit and around the furin cleavage sites compared to the SC2.S1.TM1 model, whose dynamic domains cover a smaller surface area only in the S1 subunit. These results suggest that the furin cleavage mutation may help mitigate the dynamics seen by S1 regions and provide mild stabilization to S2.

We further investigate the effect that the furin cleavage mutation has on the S2 subunit by comparing the dynamic

patterns of SC2.S1.TM1 to the WT protein. The unresolved regions in SC2.S1.TM1 are removed from the WT to create WT'-A (Fig. S1 B). The results indicate that the general pattern of dynamics is preserved in WT'-A. Specifically, dynamic domains within WT'-A cover the same S1 regions as in WT (Fig. S1 B; Fig. 2, C and D). Additionally, two dynamic domains exist at furin cleavage sites and extend into the S2 subunit, similar to the other WT models presented in Effect of glycans and structural resolution on WT ANM dynamics. Although SC2.S1.TM1 contains additional mutations, it is clear that the WT protein displays a propensity for naturally flexible regions in the S2 subunit and an unstable S1/S2 junction.

Together, the comparison of dynamical patterns between SC2.S2.TM1-1, WT, and their controls demonstrates that structures without stabilizing furin cleavage mutations may have a propensity to exhibit flexibility in the S2 subunit. Furin cleavage mutations individually may provide a mild stabilizing effect to the S2 subunit by modulating the response at the S1-S2 junction. However, this action may be highly sensitive to the presence of other mutations because we see more consistent and pronounced dynamic domains in the S2 subunit of the WT than of SC2.S2.TM1-1. Furthermore, experimental observations of SC2.S2.TM1-1 note that GAGS furin cleavage mutation promotes disorder between the S domains (69). It may be possible that disorder-related flexibility of the furin cleavage site is a mechanism that controls the S1-S2 junction stability and force transmissibility from RBD motion of S1 to the S2 subunit. Lastly, we note that most S protein sequences containing furin cleavage mutations in this study display a moderate to high increase in thermal stability. However, given the variability in protein sequence, it is difficult to identify whether this is only due to the presence of the furin cleavage mutation or multiple mutational factors.

Effects of NTD editing

Insertions and deletions of amino acids in the NTD of the S protein are also common mutations in the presented variants. In this section, we consider SC2.N1.C1.2P.TM2 (PDB: 6XF6), SC2.C1.2P.TM4 (PDB: 6XM0), and SC2.C1.2P (PDB: 7CN9), which all contain NTD clip mutations. We do not identify a unifying defining feature among proteins that contain the NTD clip mutation, which is likely due to their sequence and structural variability. Signal peptide mutations are one subset of NTD mutations, occurring in S protein mutants SC2.S2.TM1-1 and SC2.S1.TM1. These present differing S2 subunit dynamics, which is likely attributed to the presence of a furin cleavage mutation in SC2.S1.TM1. Interestingly, SC2.N1.C1.2P.TM2 displays an auxiliary dynamic domain in the S2 region. This is not a common pattern associated with proteins that have the GSAS furin cleavage and 2P mutations. This result suggests that NTD-related mutations may augment the level of stability provided by the furin cleavage region. Removal of the

NTD amino acids may disrupt protein stability, causing stabilizing furin cleavage mutations to be less effective. Addition of signal peptides may reinforce the furin cleavage site or may cause significant dynamical changes in S1 regions. Given the variability that results from introducing different signal peptides or NTD deletions, it remains difficult to definitively predict the dynamical and functional implications of a certain class of NTD editing.

We find that the location of an NTD mutation has an effect on resulting dynamics. The first 32 residues are most commonly changed via signal peptide or deletion (see sequence breakdown in the [Supporting materials and methods](#)). Within the WT protein, residues 13–32 are located on the underside of the NTD in close proximity to the S1-S2 junction (Fig. 6). By contrast, within the SC2.TM4-1 structure, for example, residue 14 (1–13 are unresolved) is located around the top portion of the NTD (17), suggesting a variability in organization of this region among S protein structures. The position of the first 32 residues may be critical for determining S1 dynamic stability. Structural change may indirectly drive dynamical and functional mechanisms through protein geometry or directly by changing the architecture of critical bonds. In particular, Lys77 and Arg80 form a salt bridge in the NTD of the WT structure. This pair exists in close proximity to residues 13–26, with residue 77 as close as 9 Å to residue 24. Alteration of the first amino acid positions by mutation may subvert critical bonds like the observed salt bridge. Additionally, any mutation to position 15 may result in the direct destabi-

lization of a disulfide bond between CYS15 and CYS136 observed by Cai et al. (12).

To further investigate the effect of NTD clip mutations, we remove all unresolved regions between SC2.N1.C1.2P.TM2, SC2.C1.2P.TM4, and SC2.C1.2P from the SC2.C1.2P structure to create the control SC2.C1.2P' and analyze the resulting modal trajectories. We remove unresolved regions from SC2.C1.2P because it has the highest-resolution unresolved regions within only 13% of the structure, in comparison to SC2.N1.C1.2P.TM2 and SC2.C1.2P.TM4, with unresolved regions amounting to 24.5 and 18.7%, respectively. The dynamics of SC2.C1.2P' show an increased number of dynamic domains in the S1 subunit compared to SC2.C1.2P (Fig. S1 C; Fig. 4 E). Next, the same unresolved regions are removed from SC2.C1.2P.TM4 to create the control SC2.C1.2P.TM4' and dynamic domain analysis is conducted (Fig. S1 D). The dynamic domain breakdown of SC2.C1.2P.TM4' shows an additional dynamic domain in the S2 subunit that is not present in SC2.C1.2P.TM4, and the dynamic domain around the RBD covers a larger surface area (Fig. S1 D; Fig. 4 G). Overall, however, the general pattern of dynamics is not disrupted when SC2.C1.2P and SC2.C1.2P.TM4 are compared with their controls. Protein deformation is, however, emphasized in the controls, which accounts for the additional dynamic domains in regions where deformation is more damped in the original structures. For example, there is some observed protein deformation in SC2.C1.2P close to residue index positions 2250 and 2750 (Fig. 3 E), whereas




FIGURE 6 Representation of the WT S protein (56) structure interior view (A) and side view (B). All mutation sites in the S protein shown are listed in Table 1. To see this figure in color, go online.

in SC2.C1.2P' this motion is more pronounced (Fig. S1 C, in orange). Comparing the original S proteins with their controls, in addition to the analysis that we perform on the WT protein, shows how removal of regions can encourage instabilities by emphasizing already present dynamic patterns. Thus, the outcome of mutations that remove portions of protein structure may likely result in a similar phenomenon. Comparison of proteins that have NTD clips does not elucidate any other apparent dynamic patterns given the other variations within the sequences. Thus, the outcome of this mutation is hypothesized to be highly sensitive to the location and magnitude of the deletion, which may be further influenced by other present mutations.

Overall, our observations highlight NTD insertion and deletion effects on structural stability and protein mobility levels. Location of the mutations and other protein sequence artifacts are likely to impact the nature of dynamical and functional mechanisms that occur because of NTD mutations. Analysis of protein structure surrounding the location of critical NTD residues highlights how mutational changes may disrupt local bonding and/or supplement S1-S2 junction stability. The comparison of SC2.C1.2P.TM4 and SC2.C1.2P to their control structures in conjunction with the WT analysis in [Effect of glycans and structural resolution on WT ANM dynamics](#) demonstrates how the removal of protein structure can emphasize protein dynamics and encourage instabilities by providing less structural support.

Effects of proline mutations

Proline mutations are common among the S protein mutants we considered in this study, occurring in all mutants except for SC2.C1.TM4-2 (71), SC2.TM4-1 (12), and the WT (72). In this section, we analyze thermal stability patterns and compare the dynamic domain composition of S protein mutants to investigate the mechanisms of S protein proline mutations. Experimental studies indicate that proline mutations increase protein thermal stability and may aid in S protein resistance against reorganization, especially when prolines are added to the backbone and/or loop positions (14,18,27,71). Our thermal stability predictions confirm that prolines increase thermal stability. There is a 0.28 J/mol thermal stability increase in the BiPro (16) sequence when prolines are added to create HexaPro (18), which has the highest measured thermal stability in our set, $\Delta\Delta G = 1.21$ J/mol. Also, the BiPro-0 sequence (42) displays a high thermal stability value, $\Delta\Delta G = 1.10$ J/mol, with just the 2P mutation. Of the structures with proline mutations, u1S2q has the lowest thermal stability value ($\Delta\Delta G = 0.32$ J/mol). Its unique quadruple mutation results in a two-RBD-up structure but may also decrease thermal stability compared with other S protein mutants (Table 1). This structure may benefit from additional prolines, e.g., as introduced in HexaPro.

Although the effects of proline mutations on thermal stability have been investigated previously (8,16,18), the impact

of proline mutations on dynamic domain decomposition is largely unknown. Of the structures that sample both open and closed conformation, only the SC2.C1.TM4-2 and WT sequences do not contain any proline mutations. All structures with proline mutations, except SC2.S2.TM1-1, contain the upper interior proline mutation (Fig. 6 C, in yellow). The HexaPro mutant contains many unique proline mutations (Fig. 6 C, in orange) and shares one proline site with SC2.C2.1P.TM3 (Fig. 6 C, in purple). To investigate the role of proline mutations, we first compare the general dynamic patterns in S protein mutants to make generalizations about proline contributions in specific sequences. Because most of the structures contain proline mutations and there is variability in sequence and structural resolution among them, it is difficult to establish a basis of comparison for a more accurate and direct assessment of individual proline mutations. However, we do compare the effects of the HexaPro 6P mutation and BiPro 2P mutation to gain more direct insight into the effect of proline mutations on structural dynamics patterns (Fig. 3, A and D). These structures have 100% alignment in their unresolved regions and thus can be directly compared without artificial controls. HexaPro presents an increased number of dynamic domains compared to BiPro, and its dynamic domains cover a wider surface area in the S1 subunit. It is possible that in the absence of other S1-stabilizing mutations, such as a signal peptide, the higher proline content of HexaPro stabilizes the S2 domain further and redistributes forces that contribute to the motion of S1 subunit domains, propelling these domains to sweep a larger surface area. Because the dynamic domains in the S1 subunit cover a larger surface area, the force per area may be lower and may contribute to decreased LDSs in HexaPro. Comparing S2 subunit dynamics between BiPro and HexaPro, the GDSs for these regions are 1.05 and 0.94, respectively, suggesting increased S2 stabilization within HexaPro. Experimentally, it has also been suggested that the 6P mutation triggers further S1 instability compared to other structures (18).

S1 subunit antigenic map and mechanisms of virus neutralization

The variability in S protein dynamics suggests that domain accessibility and mobility patterns associated with S protein mutants may influence the number and positioning of neutralizing antibodies that can bind to S proteins. To investigate the relationship between solvent accessibility and the location of dynamic domains, we calculated the change in solvent accessibility over the course of modal trajectories (Figs. 3, 4, and 5 *iii*). SASA deformation closely correlates with NMA deformation patterns, and dynamic domains are characterized by larger variability in solvent accessibility, as expected.

To investigate whether and how the location and flexibility of dynamic domains influence antibody binding, we

created an S1 subunit antigenic map and characterized the neutralizing mechanisms associated with different antibody binding regions on the S protein (Fig. 7). The antigenic map was created from an exhaustive literature review of SARS-CoV-2 related antibodies and their epitope data (Table S1). All epitope positions were mapped onto our WT model. Their location on this model, combined with binding characteristics from all available antibodies, formed the basis of the defined zones. Epitope positions in zone 1 are 392, 403–421, 428–430, 444–458, 472–486, and 515–517; in zone 2 are 439, 470, 487–498, and 505–505; in zone 3 are 440–445, 343–346, and 368–374; in zone 4 are 347–360, 370–390, 405–418, and 376–380; and in zone 5 are 145–150 and 246–250 (Fig. 7). We note that residues in each zone may shift because of RBD refolding in response to mutations, binding, or other structural modifications. The zones are limited to the S1 subunit because there is more literature characterizing antibodies that bind to S1, and in association, possible competition with ACE2 provides a direct neutralizing action (12,17). There is less literature characterizing SARS-CoV-2 antibodies that bind to the S2 region; it is presently unclear whether this is due to research bias or because antibodies dominantly bind to the S1 domain. These may stabilize the structure into a neutralizing configuration or compete with ACE2 receptor binding directly (19,22). Although antibodies can bind to other regions of the SARS-CoV-2 S protein, these are not well documented (76). The S protein antigenic map is suspected to exist as a continuum rather than as discrete zones. However, based on our current understanding of S1 epitopes, defining them by zones informs the differentiation between binding mechanisms to the S protein. The SC2.S1.TM1, BiPro, and HexaPro sequences are studied most commonly in antibody binding studies. In Table S1 and Fig. 7, the binding zone, neutralizing effect, and related prefusion trimer structures are categorized. If an antibody is studied in relation to a freely expressed RBD that is associated with a prefusion trimer or docked to one computationally, then it is marked as unknown. This analysis shows that potent neutralizing antibodies bind to the S protein in all zones. However, the mechanisms for neutralization are different, and contact with any binding zone does not guarantee potent neutralization. All epitope positions were mapped onto our WT model, including the location of each antibody and binding characteristics (Fig. 7 B).

Zone 1 (Fig. 7 A) exists on the inside and top of the RBD—it is largely hidden when an RBD is closed and is fully exposed when an RBD is rotated vertically by way of hinge fluctuations. Thus, antibodies can only bind to zone 1 fully when the RBD is in the up conformation. For many of the antibodies that bind to the RBD in zone 1, their mode of action is direct blocking of the ACE2 binding site (19,20,26,77,78). These antibodies fully or partially overlap with ACE2 binding positions (19). The antibody can simultaneously support neutralization by producing steric clashes

with ACE2 such that it cannot bind to other exposed binding regions (19).

The neutralization action provided by antibodies that bind or partially bind to zone 2 (Fig. 7 A) is varied. Zone 2 exists around the top and exterior of the RBD, and it can be recognized while the RBD is in up and down configurations. Some antibodies, such as REGN10987, are suspected of shifting zones as the RBD fluctuates and moves into ACE2 competing positions (19,79). Many antibodies that target zone 2 act as bridges between adjacent RBDs or between other antibodies (19). This may influence the RBD's ability to lock on to ACE2 by inducing conformational changes or by blocking ACE2 sterically (19). For example, C144 is able to attach to adjacent domains and lock the trimer into a closed position so that it cannot interact with ACE2 (19).

Zone 3 (Fig. 7 A) is located underneath zone 2 on the exterior of the RBD, making it easily accessible in both open and closed states. Because it does not overlap with the ACE2 binding site or exist in close proximity, the neutralizing effects are suspected to be caused by conformational changes or blocking of ACE2 by steric clashes (19,26,28). In cases of weak neutralization, the conformational changes needed for potent neutralization may not be accessible or the ability to clash with ACE2 is mild (26). In cases of higher potency, this may not be the case. Importantly, antibodies that bind in zone 3 may allow space for other neutralizing antibodies to bind to RBD regions and work together to create a neutralizing cocktail (79). For example, S309 and S2E12 work together to stabilize RBDs in the down position and hide receptor-binding sites (24).

Zone 4 (Fig. 7 A) is located on the side regions of the RBD. These epitopes have been labeled as “cryptic epitopes” in other studies (19,20). Zone 4 is only fully accessed in the RBD-up configuration. However, this region may be partially accessed in the down position if an antibody is bound elsewhere. In most cases in which this cryptic epitope is accessed, a multi-RBD-up structure would be optimal, as this would create space for more stable binding (5,80). Unless the up RBD is fully extended, binding in zone 4 may cause further conformational shifts to an unstable multi-RBD-up structure or a stabilized open structure (10,17,19,26). These scenarios may again inhibit the ability of the RBD to lock into ACE2 and form stable interactions.

Lastly, zone 5 (Fig. 7 A) is located around the tip of the NTD. There have been fewer documented cases of antibodies binding to this region, but examples include 4AH (75,76) and Ab4-8 (22). Interestingly, antibodies that bind in this zone have been seen to produce potent neutralizing effects. They can bind to the NTD in both up and down positions and do not clash with ACE2 binding regions. The neutralization mechanisms of these antibodies remain largely unclear, although Chi et al. note that antibodies




FIGURE 7 (A) S protein antigenic map with epitope zones labeled in different colors. The color bar provides a Venn diagram showing the zone associated with each of the studied antibodies (see Table S1). Above the color map, sequence positions of defined epitopes are labeled in association with each zone. (B) The location of epitopes (black regions) from all zones are mapped onto deformation and solvent-accessibility plots for (i) BiPro (16), (ii) SC2.S1.TM1 (8), and (iii) HexaPro (18) to show the overlap between epitope zones and dynamic domains. To see this figure in color, go online.

that bind to the NTD may provide some stabilizing effect (75). Our dynamics analysis of S proteins with signal peptide mutations shows that additions made to the NTD can

provide a stabilizing effect (Fig. 2; Table 1). Thus, based on our analysis, it is plausible that antibodies targeting the NTD can provide additional neutralization support.

Each S protein mutant has a different family of mutations (Table 1) and produces unique dynamic patterns associated with a specific level of stability. We find that these patterns directly correlate with the antibody binding propensity and binding mechanisms for different S protein mutants. This is quantified in Fig. 7 B, in which the locations of known epitopes (in black) are mapped onto deformation and solvent-accessibility profiles for BiPro, SC2.S1.TM1, and HexaPro. The locations of known neutralizing epitopes directly overlap with the locations of dynamic domains. At the same time, there are certain areas where dynamic domains do not overlap with an identified epitope location. For example, the yellow and purple dynamic domains on the BiPro structure (Fig. 7 B i) cover entire NTDs and do not overlap with black epitope regions. Given that known epitopes and dynamic domains correlate significantly, these regions may indicate additional antibody targeting sites outside of those already found experimentally.

BiPro and HexaPro structures, containing epitopes in all of the defined zones, are recognized by a variety of antibodies. Interestingly, the epitopes of these structures may be predicted from their dynamic domain patterns (Fig. 3, A and D). BiPro and HexaPro present dynamic domains that cover a larger surface area in the S1 subunit domains. The up RBDs are considered dynamic domains, or regions of a dynamic domain in the case of HexaPro, corresponding to zones 1 and 2. In some cases, binding in zone 2 may require structural reorganization or binding to adjacent RBDs. The presence of dynamic domains in these same regions highlights the structure's ability to adjust and be made available to secondary antibody contacts or structural manipulations. Also, the presence of dynamic domains surrounding the NTD shows that this area may be receptive to binding with other proteins.

Unlike BiPro and HexaPro, the SC2.S1.TM1 S protein has epitopes concentrated in zones 1 and 4, with some overlapping with zone 3. Because of its location (Fig. 7 A), zone 3 is easily accessed in both open and closed states. Zone 3 can likely be recognized regardless of S protein state or stability. The presence of a fluctuating RBD exposes zone 1. Thus, we would expect to identify epitopes associated with zone 1 because SC2.S1.TM1 samples open and closed states, and this is confirmed in our dynamic domain analysis (Fig. 4 H). It may be the case that the structural stability of the closed RBDs and mobility experienced by the open RBD create an accessible space in zone 4 and allow for recognition by antibodies. The SC2.S1.TM1 structure is associated with more epitopes in zone 4 than BiPro and HexaPro structures by percentage. The SC2.S1.TM1 structure is also not associated with epitopes in zone 2. Antibodies that bind in zone 2 commonly create bridges with adjacent RBDs and present other conformational changes. In our dynamics analysis, we find that the down RBDs are more stabilized and inclined to adopt the down position over the up position, thereby reducing RBD movement and exposure of addi-

tional antibody binding zones. This observation suggests that secondary antibody contacts may be essential for the longevity and stability of neutralizing antibodies. Secondly, the stability associated with the closed RBDs within the S1 subunit, as in the SC2.S1.TM1 structure, hinders the ability of antibodies to stably connect and reorganize S1 subunit domains.

We next calculate the dynamic domain overlap percentage (Fig. 8) with the defined antibody zones for each SARS-CoV-2 S protein mutant listed in Table 1. The percent overlap is calculated with respect to the number of residues within dynamic domains, giving a measure of the total dynamic domain space that overlaps with known antibody binding zones. High percent overlap, scaled by the dynamic domains, indicates that the protein may not present additional antibody binding areas outside of the defined zones. Percent overlap is also calculated with respect to the number of residues within antibody binding zones, giving a measure of the total zone space overlapping with dynamic domains. High percent overlap, scaled by antibody zones, indicates that protein dynamic domains overlap significantly with the defined binding zones. Thus, the most desired combination, in consideration for S protein design, could target low overlap with respect to dynamic domains (which would indicate the potential for additional antibodies) and high overlap with respect to antibody binding zones. Among the structures considered here, this result is best exemplified by the u1S2q mutant.

We find that the u1S2q mutant has the highest overlap between dynamic domains and antibody binding zones, at 68.2 and 17.5% overlaps, respectively (Fig. 8). These values indicate that the protein dynamics result in high exploration of antibody binding zones and simultaneously regions outside of these zones. Based on this result, we hypothesize that two-RBD-up S proteins garner increased neutralizing activity as compared with, for example, single-RBD-up S proteins. Results from the dynamics analysis of the two-RBD-up structures (Figs. 1 and 3) suggest that one RBD is highly dynamic and retains a higher propensity to flip between open and closed orientations, whereas the other RBD is less mobile. Dynamic domains are also present at all three NTDs. Based on our findings and results of experimental studies (17), the flexibility of the NTDs is essential for the structure to accommodate two up RBDs. Multi-RBD-up structures expose a greater number of epitope zones. Therefore, the existence of additional dynamic domains around these sites may confer sufficient flexibility to allow for several possible antibodies binding at the same time. We note that alternatively, excessive mobility of these RBDs may hinder antibody binding and destabilize critical bonds. We expect that future design of S protein mutants will benefit from these considerations.

Based on our observations of one-RBD-up S protein dynamics and analysis of the percentage overlap results, we find that structures that present dynamic domains covering a large surface area in the S1 subunit are more likely to




FIGURE 8 Percentage overlap between dynamic domains (DDs) and antibody binding zones for different spike protein mutant. W.R.T., with respect to. The blue bar indicates how much of the dynamic domain space overlaps with known antibody binding regions. The orange bar indicates the amount of antibody zones overlapping with dynamic domains. To see this figure in color, go online.

expose a variety of epitope zones and possess the mobility needed for conformational change in response to antibody binding. Out of the structures we have analyzed, u1S2q, BiPro, HexaPro, BiPro-1, and SC2.C2.1P.TM3 are predicted to elicit the most varied and neutralizing antibody response while remaining stabilized at the S2 subunit. The SC2.S2.TM1-1 S protein presents dynamic domains that cover significant surface area and a low percentage overlap with respect to dynamic domains, indicating varied antibody response as well. However, this structure also presents dynamic domains in the S2 subunit. These dynamic domains may represent an additional region for antibody targeting, but we predict that this instability can also increase virus-cell fusion efficacy through significant structural shifts. The SC2.S2.TM1-1 S protein may be a candidate for a cocktail of antibodies that target both S1 and S2 subunits in the manner that is described by Chi et al. (75) and Pinto et al. (30).

Antibodies bound to SARS-CoV-2 S protein influence local domain dynamics

We next constructed ANMs for SARS-CoV-2 S proteins bound to neutralizing antibodies in each of the defined zones and found their associated modal trajectories. Dynamics analysis was performed to characterize neutralizing mechanisms further and determine how antibody contacts may influence S protein stability. The starting PDB structures used for analysis are PDB: 7K4N (24), 7BYR (21), 7K43 (24), 7JW0 (26), and 7C2L (75) and include antibodies covering all zones (Fig. 8). We note that the structural and dynamical properties associated with each zone may not hold for all antibodies that bind to that zone. We also compute deformation and solvent-accessibility profiles for each antibody-

bound S protein, as in [Effect of glycans and structural resolution on WT ANM dynamics](#), to highlight new, to our knowledge, dynamical patterns associated with antibody-bound structures (Fig. 9).

The SARS-CoV-2 BiPro S protein mutant binds to antibody S2E12 in zone 1 (PDB: 7K4N) (24). This combination leads to highly potent neutralizing action by the antibody overlapping with the ACE2 binding site (24). As with most zone 1 antibodies, S2E12 can only bind to the S protein when its RBD is in the up conformation (24). Enzyme-linked immunosorbent (ELISA) assays confirm this, showing solutions containing closed trimer structures with very low neutralizing action compared to solutions containing RBD-up S proteins (24). The BiPro sequence displays a propensity to reorganize into a multi-RBD-up structure upon binding, as confirmed by our analysis of its local domain dynamics (Fig. 3 A) (16,24). Such reorganization is believed to take place in the BiPro protein, enabling it to adopt a three-RBD-up conformation in which each RBD is bound to an antibody (24). Dynamic domain analysis of BiPro bound to S2E12 ANM (Fig. 9 A) reveals dynamic domains around two of the up RBDs bound to antibodies, whereas the third is stabilized. Thus, as expected, antibodies provide some structural stabilization to the S protein in addition to neutralization by ACE2 competition. LDSs and GDSs for this structure are indeed lower than those of BiPro, pointing to S protein stabilization. Cryo-EM characterization of the complex confirms that antibody binding has a stabilization effect, noting that it dramatically improves protein resolution (24).

The BD23 antibody binds to the BiPro S protein mutant in zone 2 (PDB: 7BYR) (16,21). The potent neutralizing action provided by BD23 is through direct overlap with the RBM on one RBD and overlap with an opposite RBD, blocking ACE2 binding on both RBDs. BD23, like many antibodies that bind in zone 2, can bind to the RBD in the up or down position. Dynamic domain analysis of the ANM model of BD23 bound to BiPro (Fig. 9 B) reveals a slightly mobile S1 domain (LDS = 0.84 compared to GDS = 0.74). The BD23 protein is determined to have two highly mobile domains (LDS = 4.48 and LDS = 2.08). The NMA trajectory (see [Video S14](#)) shows that BD23 stabilizes the RBD and fluctuates in a hinge-like motion, enabling it to interact with the neighboring closed RBDs. In experimental studies, BD23 is suspected to act similarly to S2E12 to stabilize S1 subunit domains while providing neutralizing activity (21). Thus, zone 2 presents a prime antibody target because it is accessible in both open and closed states but can still provide potent neutralization through ACE2 competition and structural stabilization.

The S2M11 antibody binds to the SC2.S2.TM1-1 at all three RBDs through a quaternary epitope in zone 3 (PDB: 7K43) (8,24). Cryo-EM data show that S2M11 can achieve its peak neutralizing ability when attaching to one-RBD-up structures because of its ability to make contacts with zone




FIGURE 9 Results of dynamic domain analysis for antibody-bound S proteins with PDB: (A *i*) 7K4N (24), (B *i*) 7BYR (21), (C *i*) 7K43 (24), (D *i*) 7JW0 (26), and (E *i*) 7C2L (75). The PDB, GDS, LDSs, deformation profile (*ii*), and Δ SASA profile (*iii*) are listed for each structure. To see this figure in color, go online.

4 as the RBD changes position (24). Upon reaching the closed position, S2M11 can lock down all RBDs while burying the RBM and paratope (24). For the SC2.S2.TM1-1 structure, the fully closed conformation may be more accessible because most of the S1 subunit region is stabilized with two of the three RBDs in the down conformation (Fig. 4 *H*) (8). The domain dynamics for the ANM model of S2M11 and S protein complex reveal dynamic domains around two of the NTDs and one of the S2M11 antibodies (Fig. 9 *C*). In the case of the two NTDs, these may need to adopt enough mobility to compensate for the locked position of the RBDs. Cryo-EM-observed states also show that S2M11 antibodies bridge neighboring RBDs (24). The dynamic domain identified around one of the antibodies (Fig. 9 *C*) may indicate weaker binding to neighboring RBDs.

The SC2.S2.TM1-1 S protein also binds to the S304 antibody (PDB: 7K43) in zone 4 and makes contacts at all RBDs that reorganize into the three-RBD-up conformation

(26). This combination leads to weak neutralization through partial ACE2 competition via steric clashing (26). The exact binding mechanisms for S304 are unclear, but based on the behavior of the other zone 4 antibody, S2A4, S304 may act like a molecular ratchet to wedge open RBDs (26). The NMA trajectory of the SC2.S2.TM1-1 and S304 model shows dynamic domains covering large portions of the S1 subunit and antibody (Fig. 9 *D*). The larger and less mobile (LDS = 1.13) dynamic domain (Fig. 9 *D i*) comprises two of the up RBDs and all three antibody fragments, and the dominant domain (purple) fluctuates independently of the rest of the structure (see Video S19). This suggests that binding to this zone 4 epitope may not stabilize the RBD position in all cases. This fluctuation may provide a means to bind to ACE2 and evade steric clashes with S304.

Lastly, S proteins also bind to the antibody 4AD in zone 5 (PDB: 72CL) at the tip of each NTD (75) Thus, the potent neutralizing action provided by this epitope involves no

direct contact with ACE2 or the RBDs (75). Cryo-EM analysis shows that the 4AD association stabilizes the NTDs, quantified by dramatically improved structural resolution (75). Analysis of the S protein bound to 4AD modal trajectory confirms this observation. It further shows stabilization of the whole S protein in the one-RBD-up confirmation and dynamic domains covering the 4AD antibody (Fig. 9 E). This highlights a possible neutralization mechanism because ACE2 is not able to bind to the S protein even in the presence of an up RBD. The stabilized RBD and hindered flexibility of surrounding regions may prevent it from fitting onto ACE2 and structurally reorganizing in response to binding. This is an example of the neutralizing potential of antibodies through indirect structural stabilization mechanisms rather than ACE2 competition. Additionally, this result suggests that the NTD is a key area to target when designing a structurally stabilized prefusion S protein. Presented findings in our study and in others demonstrate that increased stability can be achieved by making mutations at the S1-S2 junction and hinge region that controls RBD fluctuation. Stabilized prefusion structures that prevent RBD fluctuation may have increased immunogenic properties by inhibiting ACE2 binding mechanisms.

Cellular fusion and receptor-binding mechanisms differ across SARS and MERS family coronaviruses

Cleavage sites inform differing cellular fusion properties

SARS and MERS family coronaviruses are similar in their viral architecture but can be widely varied in sequence and biological virus effects (8,81). A key difference between SARS-CoV-2 and other coronaviruses is its widespread and pernicious nature—a key characteristic believed to be rooted in the S protein's function (81). Although S proteins from SARS-CoV-2, SARS-CoV, and MERS-CoV all adopt the characteristic trimer structure, they differ in sequence, specifically, at their cleavage sites (13). Cleavage of S proteins is required for fusion of viral and cell membranes. Cleavage site sequence encodes which cell receptors can be recognized by the S protein and can therefore modulate cell-virus fusion efficacy (13,79). SARS family S proteins recognize ACE2 cell-surface receptors, whereas the MERS-CoV S protein recognizes DPP4 (1,75,79,82). The combination of R|SV and R|SF cleavage sites within the SARS-CoV-2 S protein is unique to SARS-CoV-2 S proteins in comparison to other coronavirus proteins (see Table 2) and is suspected to render SARS-CoV-2 WT S proteins highly recognizable by furin, an abundant enzyme in respiratory environments (13). Unlike SARS-CoV-2, SARS-CoV contains an R|ST S1/S2 cleavage site and MERS-CoV contains an R|SA cleavage site at S2', which may provide an additional immune mechanism that accounts for their less-widespread nature.

Comparison of SARS-CoV-2 and MERS S protein dynamics suggests potential immune escape mechanisms

We also investigate the dynamic and mechanistic differences between SARS-CoV-2 and MERS-CoV S proteins. Specifically, we examine the MC.SD.TM1 MERS-CoV S protein that adopts both one-RBD-up (PDB: 5X5F) and two-RBD-up (PDB: 5X5C) conformations (80). This sequence has stabilizing S1/S2 cleavage mutations, NTD clip, and trimerization motif mutations as compared to the Uniprot: K9N5Q8 MERS-CoV sequence (80). We measure a 94% alignment between the two sequences. Our model of the one-RBD-up structure (PDB: 5X5F) shows a dominant dynamic domain surrounding the up RBD and auxiliary dynamic domains presented on either side of the RBD (Fig. 10 A). This breakdown is similar to the dynamic patterns seen in SARS-CoV-2 models (Figs. 3, 4, and 5). The two-RBD-up model of MC.SD.TM1 (PDB: 5X5C) presents dynamic domains surrounding both up RBDs and their adjacent NTDs (Fig. 10 B) in the same manner as u1s2q. Also, the dynamic domain signatures of the two-RBD-up MC.SD.TM1 MERS-CoV S protein model and two-RBD-up u1S2q SARS-CoV-2 S protein model (Figs. 3 C and 10 B) resemble one another, and the only divergence between them is in an additional dynamic domain around MC.SD.TM1's down RBD. Interestingly, the MERS-CoV two-RBD-up configuration exhibits these behaviors without the presence of the A570L, T572I, F855Y, and N856I mutations observed in the SARS-CoV-2 u1S2q sequence. These dynamics in the MERS-CoV S protein suggest that it may be naturally more flexible in the S1 domain compared with SARS-CoV-2. Additionally, the increased solvent exposure and level of RBD fluctuation presented by MERS-CoV S proteins with up RBDs may increase neutralizing antibody activity, as shown by the experimental immunogenic studies on u1S2q (17). These RBD-linked mechanisms likely contribute to MERS-CoV's localized spread in contrast to the SARS-CoV-2 global spread.

Comparison of SARS-CoV and SARS-CoV-2 S protein dynamics suggests potential immune escape mechanism

We characterize the structural and dynamical differences between SARS-CoV-2 and SARS-CoV by constructing ANMs and performing dynamic domain analysis on resulting NMA trajectories (Figs. 3, 4, 5, and 10 C). Multi-RBD-up prefusion SARS-CoV S proteins are not currently available in the PDB; therefore, we analyze the one-RBD-up structure, SC1.TM1 (PDB: 6ACD) (83). This S protein contains an S1/S2 alanine mutation compared to the WT, NCBI reference sequence: NP_828851.1 (83). An earlier study shows that this mutation does not significantly affect structural orientation but does impact ACE2 fusion properties (83). Dynamics analysis of the SC1.TM1 ANM (Fig. 10 C) shows a dominant dynamic domain around the up RBD and adjacent NTD and another auxiliary domain

TABLE 2 Comparison of SARS and MERS cleavage sites and sequence similarity to SARS-CoV-2

| Virus | S1/S2 site | S2' site | Similarity with SARS-CoV-2 | References |
|------------|------------|----------|----------------------------|---|
| SARS-CoV-2 | SPRRAR SV | KR SF | 100% | Coutard et al. (13) |
| SARS-CoV | TVSLLR ST | KR SF | 73% | Coutard et al. (13), Yuan et al. (80) |
| MERS-CoV | TPRSCR SV | AR SA | 31% | Coutard et al. (13), Yuan et al. (80), Li et al. (82) |

opposite to the up RBD. This breakdown is similar to the dynamic domain patterns seen in SARS-CoV-2 models (Figs. 3, 4, and 5). However, the maximal deformation for SC1.TM1 ANM is ~ 10 Å around its RBD, whereas the maximal deformation for one-RBD-up SARS-CoV-2 S protein mutants typically ranges between 6 and 8.5 Å. This spurs the hypothesis that there may be an RBD fluctuation window that optimizes its ability to lock onto ACE2. Our results from SARS-CoV-2 antibody binding studies suggest that static or slightly fluctuating single up RBDs may hinder ACE2 binding. The results of the SARS-CoV structure demonstrates that a highly fluctuating RBD may also hinder ACE2 binding, possibly providing a reason for its localization.

Analysis of SARS and MERS family antibody-bound S proteins informs SARS-CoV-2 antibody targets

Lastly, we constructed ANMs for SARS-CoV and MERS-CoV S proteins bound to neutralizing antibodies and performed dynamic domain analysis on their resulting modal trajectories to see if these presented any key differences to SARS-CoV-2 results. Full antibody-bound trimer structures for these coronaviruses are not as prevalent as those associated with SARS-CoV-2, so we performed analysis on MERS-CoV complex (PDB: 5W9K (84)) and SARS-CoV complex (PDB: 6NB6 (25)) as case studies (Fig. 10).

MERS-CoV S protein MC.TM1 structure bound to the neutralizing antibody G4 (PDB: 5W9K) (84) deviates in behavior from all other complexes we have examined because G4 is bound to the S2 domain near the trimer base. The mode of neutralization is extreme stabilization to prevent S2 structural reorganization upon receptor binding and thus prevention of cellular fusion (27). Based on the dynamic patterns of the G4-bound MC.TM1 model (Fig. 10 D), the S2 domain of MC.TM1 and connecting antibody regions are structurally stabilized. Dynamic domains exist in the S1 subunit around the up RBDs. The G4 antibody may not only stabilize local dynamics but global oscillations as well. From our analysis of SC2.TM4-1 and the SARS-CoV-2 WT structure, we find that the portion of the trimerization motif and C-terminal domain that makes con-

tact with the virion surface may contribute to global rocking motions experienced by the trimer around a hinge site. The MERS-CoV trimerization motif may generate a similar effect on global motions. Even without a resolved trimerization motif, MC.TM1 does present the lowest GDS seen among all other structures considered here. The neutralization capacity of S2-binding MERS-CoV antibodies presents another mechanism that may not yet be available to SARS-CoV-2 and contributes to the localized spread of MERS-CoV. Targeting antibodies that attach to the base of the trimer may be particularly effective for SARS-CoV-2 S proteins that have a propensity to exhibit unstable S2 dynamics such as the WT protein or SC2.S2.TM1-1 mutant.

The SARS-CoV S protein SC1.S1.TM2 structure bound to an S230 antibody fragment (PDB: 6NB6) shows that S230 makes contact with the tip of the up RBD and ratchets open the opposite RBD to create a bridge between the two RBDs (25). The neutralization action is generated by a direct overlap of the ACE2 binding site by the antibody. Dynamics analysis of the S230-bound SC1.S1.TM2 ANM modal trajectory (Fig. 10 E) reveals dynamic domains around the S230 and SC1.S1.TM2 RBD group and another around the neighboring NTD. Because the RBDs and antibodies form a single dynamic domain, this interaction between the proteins is suspected to be firm and resistant to deformation, providing an auxiliary neutralization mechanism. This trait is also exhibited by SARS-CoV-2 structures (see Table S1). This result provides further evidence that the antibody binding characteristics of the SARS-CoV S protein are similar to SARS-CoV-2.

CONCLUSIONS

The results presented herein, synthesized together with prior experimental data, highlight the viability of elastic network modeling, integrated NMA, thermal stability predictions, and dynamic domain analysis to characterize the structure, dynamics, and associated functions of coronavirus S proteins. We provide a review of the local dynamic patterns and associated implications of common SARS-CoV-2 mutations. We find that alterations in trimerization motifs affect trimer thermal stability and contribute to the overall level of global dynamics experienced by the structure. Changes to the first 32 residues through added signal peptides or deletions of residues may alter the stability of the NTD region by disrupting critical bonds. Indirect destabilization may occur through changes in protein dynamic patterns within domains adjacent to critical bond sites and the S1/S2 junction. We show that SARS-CoV-2 S proteins may also be structurally and dynamically sensitive to S1/S2 furin cleavage mutations, which have the potential to augment the level and distribution of force transmitted to either subunit by the oscillation of the RBD. For example, the GAGS mutation may provide a mild stabilizing effect to the S2 domain and restrict dynamic domains to the S1 subunit, although




FIGURE 10 Comparison of dynamic domain analysis results for one-RBD-up MERS-CoV (80) (A i), two-RBD-up MERS-CoV (80) (B i), and one-RBD-up SARS-CoV (83) (C i) S proteins. Results of dynamic domain analysis for antibody-bound MERS-CoV S protein PDB: 5W9K (84) (D i) and SARS-CoV S protein PDB: 6NB6 (25) (E i) are shown. The PDB, GDS, LDSs, deformation profile (ii), and Δ SASA profile (iii) are listed for each structure. Dynamic domains are highlighted in different colors. To see this figure in color, go online.

this may not always be the case if destabilizing NTD mutations are present. Proline mutations in the S2 subunit may not dramatically affect local dynamics, although they may help to partially stabilize S1 subunit dynamic regions by providing a more heterogeneous force distribution across the structure. Our thermal stability predictions, however, did show that proline mutations improve thermal stability, as expected. We also found that thermal stability may be improved through specific furin cleavage mutations. Additionally, mutations that support multi-RBD-up structures—such as those introduced in the u1S2q sequence—may decrease thermal stability, so these structures may benefit from additional proline mutations, for example.

We synthesize available experimental SARS-CoV-2 antibody binding data to create a SARS-CoV-2 antigenic map and label known antibody binding zones. By comparing local dynamics of S protein mutants, we find that it is

possible, using our models, to predict the accessibility of known epitope zones and thereby predict the binding properties of SARS-CoV-2 S protein mutants. This can be valuable information for determining which S protein variants to use for immunogen design. Thus far, we predict u1S2q, Bi-Pro, HexaPro, BiPro-1, and SC2.C2.1P.TM3 to elicit the most varied antibody response. We present case studies of SARS-CoV-2 trimers bound to antibodies in each zone, showing that antibodies affect protein dynamics, which can influence mechanisms of neutralization. Some directly overlap with ACE2 binding sites (only accessed in the RBD-up conformation); in this case, there is a direct neutralizing mechanism. When antibodies are bound to other zones, they can block ACE2 binding directly and/or induce dynamic perturbations that shift S proteins into a neutralizing configuration. Alternatively, antibodies can also initiate neutralizing conformational changes such as

bridging a multi-RBD-up structure or stabilizing NTD regions to prevent RBD-ACE2 binding shifts. Overall, our models can predict new regions of viable epitopes, as these show a strong correlation with the location of dynamic domains.

We also presented analysis of free SARS-CoV and MERS-CoV trimers and trimers bound to antibodies. We found dynamic mechanisms through which multi-RBD-up structures may impair binding to cell receptors and elicit a more varied antibody response. MERS-CoV S proteins show a higher propensity to adopt multi-RBD-up structures than SARS-CoV-2 S proteins, which may account for their more limited and localized infection. SARS-CoV S proteins do not adopt multi-RBD-up conformations as frequently, but their RBD fluctuations may induce larger deformations than in SARS-CoV-2 S proteins, which may impair their ability to lock on to cell receptors. Additionally, the S1-S2 junction for SARS-CoV proteins presents a different furin cleavage motif than MERS-CoV and SARS-CoV-2 proteins, which further impairs cellular fusion. By comparing local domain dynamics associated with all S proteins, we found that the arginine residues surrounding the furin cleavage site in SARS-CoV-2 WT S protein may account for the mechanism for S2 subunit destabilization. S2 subunit destabilization and the presence of a dynamic domain in the S2 subunit point to significant structural shifts upon binding and thus better virus-cell fusion for the SARS-CoV-2 S protein.

Dynamics analysis of SARS-CoV and MERS-CoV trimers bound to antibodies suggests that the antibody binding mechanisms of SARS-CoV S proteins may not differ significantly from SARS-CoV-2 S proteins. The MERS-CoV S protein structure presents a unique S2 epitope not seen in cryo-EM studies of SARS-CoV-2. The G4 antibody binds to the base of the trimer close to the start of the trimerization motif. This antibody provides strong S2 stabilization and is suspected to decrease the level of global dynamics by stabilizing the trimer against the virion surface. Based on these results, we suspect that S2-subunit-targeting antibodies may present strong neutralizing and stabilizing effects in the SARS-CoV-2 S protein as well. Extensive studies have not been performed on S2-targeting antibodies for SARS-CoV-2, so this could be a new avenue for research (85).

Our recommendation for the molecular design of a SARS-CoV-2 S protein immunogen is to create a multi-RBD-up structure whose RBD dynamics fall on either end of a spectrum of flexibility: either significant fluctuation or, by contrast, enhanced stability. The latter may be more easily designed. Key mutations for creating such a structure would be GSAS furin cleavage site; 6P in S2; A570L, T572I, F855Y, and N856I; and stabilizing the trimerization motif. This design is predicted to increase the number of accessible neutralizing epitopes, stabilize S2 subunits, enhance the multi-RBD-up structure, and increase thermal stability. Increased proline mutations may also inhibit structural reorganization upon ACE2 binding and more evenly

distribute any dynamic domains presented in the S1 subunit. The addition of a signal peptide may create an additional bridge near the S1-S2 junction and promote stabilization of NTDs and S2 subunits. However, it is unclear whether this will improve antibody binding properties or render the structure unable to adjust to antibodies that require conformational change.

Methods for quick characterization of coronavirus systems are essential to investigate future mutations of the SARS-CoV-2 virus and other coronavirus infectious disease outbreaks and to develop treatment and prevention options. Our study proposes an integrated framework to characterize such proteins and evaluate their functional regions. The findings presented in this study can be used to further SARS-CoV-2 immunogen design and vaccine applications. SARS-CoV-2 is mutating at an alarming rate, and unique variants are emerging in different regions of the world. For example, a new common variant has emerged in the UK that is becoming progressively prevalent in other areas of the world (86). Thus, future directions of this work include the comparison of emerging SARS-CoV-2 S protein variants to predict their effects and recommend molecular design solutions.

SUPPORTING MATERIAL

Supporting material can be found online at <https://doi.org/10.1016/j.bpj.2021.11.009>.

AUTHOR CONTRIBUTIONS

G.K., M.M., and A.T. conceived and designed the research. G.K. developed the elastic network models and performed normal mode analysis, designed the dynamic domain characterization algorithm, and performed sequence and structural analysis. M.M. developed the thermal stability predictor. G.K. and A.T. wrote and edited the final manuscript with input from all authors.

ACKNOWLEDGMENTS

This work was supported by the University of Connecticut Office of the Vice President for Research (OVPR) Covid-19 Rapid Start Funding Program. This work utilized the Extreme Science and Engineering Discovery Environment (XSEDE), which is supported by National Science Foundation grant number ACI-1548562 (79). XSEDE resources Stampede 2 and Ranch at the Texas Advanced Computing Center and Bridges at the Pittsburgh Supercomputing Center through allocation TG-MCB180008 were used.

SUPPORTING CITATIONS

References (87–103) can be found in the [Supporting material](#).

REFERENCES

1. Li, F. 2016. Structure, function, and evolution of coronavirus spike proteins. *Annu. Rev. Virol.* 3:237–261.

2. Bullough, P. A., F. M. Hughson, ..., D. C. Wiley. 1994. Structure of influenza haemagglutinin at the pH of membrane fusion. *Nature*. 371:37–43.
3. Chen, J., J. J. Skehel, and D. C. Wiley. 1999. N- and C-terminal residues combine in the fusion-pH influenza hemagglutinin HA(2) subunit to form an N cap that terminates the triple-stranded coiled coil. *Proc. Natl. Acad. Sci. USA*. 96:8967–8972.
4. Chan, D. C., D. Fass, ..., P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. *Cell*. 89:263–273.
5. Malashkevich, V. N., B. J. Schneider, ..., P. S. Kim. 1999. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-Å resolution. *Proc. Natl. Acad. Sci. USA*. 96:2662–2667.
6. Hoffmann, M., H. Kleine-Weber, ..., S. Pöhlmann. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*. 181:271–280.e8.
7. Munster, V. J., M. Koopmans, ..., E. de Wit. 2020. A novel coronavirus emerging in China - Key questions for impact assessment. *N. Engl. J. Med.* 382:692–694.
8. Walls, A. C., Y.-J. Park, ..., D. Veelsler. 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell*. 181:281–292.e6.
9. Wan, Y., J. Shang, ..., F. Li. 2020. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. *J. Virol.* 94:e00127-20.
10. Zhou, D., H. M. E. Duyvesteyn, ..., K. A. Huang. 2020. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. *Nat. Struct. Mol. Biol.* 27:950–958.
11. Walls, A. C., M. A. Tortorici, ..., D. Veelsler. 2017. Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. *Proc. Natl. Acad. Sci. USA*. 114:11157–11162.
12. Cai, Y., J. Zhang, ..., B. Chen. 2020. Distinct conformational states of SARS-CoV-2 spike protein. *Science*. 369:1586–1592.
13. Coutard, B., C. Valle, ..., E. Decroly. 2020. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral Res.* 176:104742.
14. Kirchdoerfer, R. N., N. Wang, ..., A. B. Ward. 2018. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. *Sci. Rep.* 8:15701.
15. Majumder, S., D. Chaudhuri, ..., K. Giri. 2021. Exploring the intrinsic dynamics of SARS-CoV-2, SARS-CoV and MERS-CoV spike glycoprotein through normal mode analysis using anisotropic network model. *J. Mol. Graph. Model.* 102:107778.
16. Wrapp, D., N. Wang, ..., J. S. McLellan. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*. 367:1260–1263.
17. Henderson, R., R. J. Edwards, ..., P. Acharya. 2020. Controlling the SARS-CoV-2 spike glycoprotein conformation. *Nat. Struct. Mol. Biol.* 27:925–933.
18. Hsieh, C.-L., J. A. Goldsmith, ..., J. S. McLellan. 2020. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. *Science*. 369:1501–1505.
19. Barnes, C. O., C. A. Jette, ..., P. J. Bjorkman. 2020. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. *Nature*. 588:682–687.
20. Yuan, M., N. C. Wu, ..., I. A. Wilson. 2020. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. *Science*. 368:630–633.
21. Cao, Y., B. Su, ..., X. S. Xie. 2020. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. *Cell*. 182:73–84.e16.
22. Liu, L., P. Wang, ..., D. D. Ho. 2020. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature*. 584:450–456.
23. Custódio, T. F., H. Das, ..., C. Löw. 2020. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. *Nat. Commun.* 11:5588.
24. Tortorici, M. A., M. Beltramello, ..., D. Veelsler. 2020. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. *Science*. 370:950–957.
25. Walls, A. C., X. Xiong, ..., D. Veelsler. 2019. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. *Cell*. 176:1026–1039.e15.
26. Piccoli, L., Y.-J. Park, ..., D. Veelsler. 2020. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. *Cell*. 183:1024–1042.e21.
27. McLellan, J. S., M. Chen, ..., P. D. Kwong. 2013. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. *Science*. 342:592–598.
28. Wrobel, A. G., D. J. Benton, ..., S. J. Gamblin. 2020. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. *Nat. Struct. Mol. Biol.* 27:763–767.
29. Juraszek, J., L. Rutten, ..., J. P. M. Langedijk. 2021. Stabilizing the closed SARS-CoV-2 spike trimer. *Nat. Commun.* 12:244.
30. Pinto, D., Y.-J. Park, ..., D. Corti. 2020. Structural and functional analysis of a potent sarbecovirus neutralizing antibody. *bioRxiv* <https://doi.org/10.1101/2020.04.07.023903>.
31. Bangaru, S., G. Ozorowski, ..., A. B. Ward. 2020. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. *Science*. 370:1089–1094.
32. Bahar, I., T. R. Lezon, ..., I. H. Shrivastava. 2010. Normal mode analysis of biomolecular structures: functional mechanisms of membrane proteins. *Chem. Rev.* 110:1463–1497.
33. Wako, H., and S. Endo. 2017. Normal mode analysis as a method to derive protein dynamics information from the Protein Data Bank. *Biophys. Rev.* 9:877–893.
34. Hu, Y., and M. J. Buehler. 2021. Comparative analysis of nanomechanical features of coronavirus spike proteins and correlation with lethality and infection rate. *Matter*. 4:265–275, Published online November 2, 2020.
35. Yamato, T., and O. Lapr evote. 2019. Normal mode analysis and beyond. *Biophys. Physicobiol.* 16:322–327.
36. Bertaccini, E. J., J. R. Trudell, and E. Lindahl. 2010. Normal mode gating motions of a ligand-gated ion channel persist in a fully hydrated lipid bilayer model. *ACS Chem. Neurosci.* 1:552–558.
37. Lynch, M. 2012. The evolution of multimeric protein assemblages. *Mol. Biol. Evol.* 29:1353–1366.
38. Wieninger, S. A., and G. Matthias Ullmann. 2015. CoMoDo: identifying dynamic protein domains based on covariances of motion. *J. Chem. Theory Comput.* 11:2841–2854.
39. Romanowska, J., K. S. Nowiński, and J. Trylska. 2012. Determining geometrically stable domains in molecular conformation sets. *J. Chem. Theory Comput.* 8:2588–2599.
40. Yesylevskyy, S. O., V. N. Kharkyanen, and A. P. Demchenko. 2006. Dynamic protein domains: identification, interdependence, and stability. *Biophys. J.* 91:670–685.
41. Dziubiński, M., P. Daniluk, and B. Lesyng. 2016. ResiCon: a method for the identification of dynamic domains, hinges and interfacial regions in proteins. *Bioinformatics*. 32:25–34.
42. Melero, R., C. O. S. Sorzano, ..., J.-M. Carazo. 2020. Continuous flexibility analysis of SARS-CoV-2 spike prefusion structures. *IUCr*. 7:1059–1069.
43. Eickholt, J., X. Deng, and J. Cheng. 2011. DoBo: protein domain boundary prediction by integrating evolutionary signals and machine learning. *BMC Bioinformatics*. 12:43.
44. Bertaccini, E. J., J. R. Trudell, and E. Lindahl. 2007. Normal-mode analysis of the glycine alpha1 receptor by three separate methods. *J. Chem. Inf. Model.* 47:1572–1579.
45. Bakan, A., L. M. Meireles, and I. Bahar. 2011. ProDy: protein dynamics inferred from theory and experiments. *Bioinformatics*. 27:1575–1577.

46. Pang, X. F. 2012. The properties of bio-energy transport and influence of structure nonuniformity and temperature of systems on energy transport along polypeptide chains. *Prog. Biophys. Mol. Biol.* 108:1–46.
47. Eyal, E., L.-W. Yang, and I. Bahar. 2006. Anisotropic network model: systematic evaluation and a new web interface. *Bioinformatics.* 22:2619–2627.
48. McGibbon, R. T., K. A. Beauchamp, ..., V. S. Pande. 2015. MDTraj: a modern open library for the analysis of molecular dynamics trajectories. *Biophys. J.* 109:1528–1532.
49. Humphrey, W., A. Dalke, and K. Schulten. 1996. VMD: visual molecular dynamics. *J. Mol. Graph.* 14:33–38, 27–28.
50. Pedregosa, F., G. Varoquaux, ..., É. Duchesnay. 2011. Scikit-learn: machine learning in Python. *J. Mach. Learn. Res.* 12:2825–2830.
51. Murtagh, F. 1983. A survey of recent advances in hierarchical clustering algorithms. *Comput. J.* 26:354–359.
52. Altschul, S. F., W. Gish, ..., D. J. Lipman. 1990. Basic local alignment search tool. *J. Mol. Biol.* 215:403–410.
53. Madeira, F., Y. M. Park, ..., R. Lopez. 2019. The EMBL-EBI search and sequence analysis tools APIs in 2019. *Nucleic Acids Res.* 47:W636–W641.
54. PyMOL. pymol.org.
55. Citing UCSF Chimera.
56. Donald, J. E., D. W. Kulp, and W. F. DeGrado. 2011. Salt bridges: geometrically specific, designable interactions. *Proteins.* 79:898–915.
57. Ma, L., N. K. Sundlass, ..., Q. Cui. 2011. Disruption and formation of surface salt bridges are coupled to DNA binding by the integration host factor: a computational analysis. *Biochemistry.* 50:266–275.
58. Amara Korba, K., and F. Arbaoui. 2018. SVM multi-classification of induction machine's bearings defects using vibratory analysis based on empirical mode decomposition. *Int. J. Appl. Eng. Res.* 13:6579–6586.
59. Abadi, M., A. Agarwal, ..., X. Zheng. 2016. TensorFlow: large-scale machine learning on heterogeneous distributed systems. *arXiv*, arXiv:1603.04467 <https://arxiv.org/abs/1603.04467>.
60. Bepler, T., and B. Berger. 2019. Learning protein sequence embeddings using information from structure. *arXiv*, arXiv:1902.08661 <https://arxiv.org/abs/1902.08661>.
61. Ranjan, C. CRAN2367/Sgt: sequence graph transform. *GitHub*, <https://github.com/cran2367/sgt>.
62. Camargo, A., K. Machado, and A. Werhli. 2015. Evaluation of computational tools for thermodynamics and structural analysis of protein stability upon point mutation prediction. In *MOL2NET, International Conference on Multidisciplinary Sciences*. MDPI, pp. 1–5.
63. Dehouck, Y., J. M. Kwasigroch, ..., M. Rooman. 2011. PoPMuSiC 2.1: a web server for the estimation of protein stability changes upon mutation and sequence optimality. *BMC Bioinformatics.* 12:151.
64. Capriotti, E., P. Fariselli, and R. Casadio. 2005. I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. *Nucleic Acids Res.* 33:W306–W310.
65. Gulli, A., and S. Pal. 2017. Keras: the Python deep learning API. *GitHub* <https://keras.io/>.
66. McKinney, W. 2010. Data structures for statistical computing in Python. *Proceedings of the 9th Python in Science Conference*, pp. 56–61.
67. Huo, J., Y. Zhao, ..., D. I. Stuart. 2020. Neutralization of SARS-CoV-2 by destruction of the prefusion spike. *Cell Host Microbe.* 28:445–454.e6.
68. RCSB Protein Data Bank. RCSB PDB - 6XF6: Cryo-EM structure of a biotinylated SARS-CoV-2 spike probe in the prefusion state (1 RBD up). <http://www.rcsb.org/structure/6XF6>.
69. Zhou, T., Y. Tsybovsky, ..., P. D. Kwong. 2020. Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains. *Cell Host Microbe.* 28:867–879.e5.
70. Liu, Y.-M., M. Shahed-Al-Mahmud, ..., C. Ma. 2020. A carbohydrate-binding protein from the edible Lablab beans effectively blocks the infections of influenza viruses and SARS-CoV-2. *Cell Rep.* 32:108016.
71. Gobeil, S. M. C., K. Janowska, ..., P. Acharya. 2021. D614G mutation alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1/S2 junction. *Cell Rep.* 34:108630, Published online December 26, 2020.
72. Casalino, L., Z. Gaieb, ..., R. E. Amaro. 2020. Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein. *ACS Cent. Sci.* 6:1722–1734.
73. Taherzadeh, G., A. Dehngangi, ..., M. P. Campbell. 2019. SPRINT-Gly: predicting N- and O-linked glycosylation sites of human and mouse proteins by using sequence and predicted structural properties. *Bioinformatics.* 35:4140–4146.
74. Wrobel, A. G., D. J. Benton, ..., S. J. Gamblin. 2020. Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein. *Nat. Commun.* 11:5337.
75. Chi, X., R. Yan, ..., W. Chen. 2020. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science.* 369:650–655.
76. Ionescu, M. I. 2020. An overview of the crystallized structures of the SARS-CoV-2. *Protein J.* 39:600–618.
77. Wu, N. C., M. Yuan, ..., I. A. Wilson. 2020. An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain. *Cell Rep.* 33:108274.
78. Yuan, M., H. Liu, ..., I. A. Wilson. 2021. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. *Biochem. Biophys. Res. Commun.* 538:192–203, Published online October 10, 2020.
79. Hansen, J., A. Baum, ..., C. A. Kyratsous. 2020. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science.* 369:1010–1014.
80. Yuan, Y., D. Cao, ..., G. F. Gao. 2017. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. *Nat. Commun.* 8:15092.
81. Rabaan, A. A., S. H. Al-Ahmed, ..., A. J. Rodriguez-Morales. 2020. SARS-CoV-2, SARS-CoV, and MERS-CoV: a comparative overview. *Infect Med.* 28:174–184.
82. Li, Y., Z. Zhang, ..., J. Lu. 2020. The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike. *iScience.* 23:101160.
83. Song, W., M. Gui, ..., Y. Xiang. 2018. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. *PLoS Pathog.* 14:e1007236.
84. Pallesen, J., N. Wang, ..., J. S. McLellan. 2017. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. *Proc. Natl. Acad. Sci. USA.* 114:E7348–E7357.
85. Van Beusekom, M.. Prepandemic coronavirus antibodies may react to COVID-19: CIDRAP News, November 9, 2020. <https://www.cidrap.umn.edu/news-perspective/2020/11/prepandemic-coronavirus-antibodies-may-react-covid-19>.
86. Gallagher, J. 2020. New coronavirus variant: What do we know? *BBC News, BBC*, December 20, 2020. <https://www.bbc.com/news/health-55388846>.
87. Wu, F., S. Zhao, ..., Y.-Z. Zhang. 2020. A new coronavirus associated with human respiratory disease in China. *Nature.* 579:265–269.
88. Rota, P. A., M. S. Oberste, ..., W. J. Bellini. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. *Science.* 300:1394–1399.
89. Bermingham, A., M. A. Chand, ..., M. Zambon. 2012. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. *Euro Surveill.* 17:20290.
90. Yuan, M., H. Liu, ..., I. A. Wilson. 2020. Structural basis of a shared antibody response to SARS-CoV-2. *Science.* 369:1119–1123.

91. Du, S., Y. Cao, ..., C. Qin. 2020. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected Hamsters and provides a potent cocktail pairing strategy. *Cell*. 183:1013–1023.e13.
92. Lv, Z., Y.-Q. Deng, ..., X. Wang. 2020. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. *Science*. 369:1505–1509.
93. RCSB Protein Data Bank.. RCSB PDB - 6ZHD: H11–H4 bound to Spike. <https://www.rcsb.org/structure/6ZHD>.
94. Hurlburt, N. K., Y.-H. Wan, ..., M. Pancera. 2020. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. *Nat. Commun.* 11:5413.
95. Kreye, J., S. M. Reincke, ..., H. Prüss. 2020. A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 Hamster model. *Cell*. 183:1058–1069.e19.
96. RCSB Protein Data Bank.. RCSB PDB - 7C8W: Structure of sybody MR17 in complex with the SARS-CoV-2 S receptor-binding domain (RBD). <https://www.rcsb.org/structure/7C8W>.
97. Ju, B., Q. Zhang, ..., L. Zhang. 2020. Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*. 584:115–119.
98. Gobeil, S. M., K. Janowska, ..., P. Acharya. 2021. Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. *Science*. 373:eabi6226.
99. Abraham, M. J., T. Murtola, ..., E. Lindahl. 2015. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. *SoftwareX*. 1–2:19–25.
100. Bussi, G., D. Donadio, and M. Parrinello. 2007. Canonical sampling through velocity rescaling. *J. Chem. Phys.* 126:014101.
101. Martonák, R., A. Laio, and M. Parrinello. 2003. Predicting crystal structures: the Parrinello-Rahman method revisited. *Phys. Rev. Lett.* 90:075503.
102. Hess, B., H. Bekker, ..., J. G. E. M. Fraaije. 1997. LINCS: a linear constraint solver for molecular simulations. *J. Comput. Chem.* 18:1463–1472.
103. Huang, J., S. Rauscher, ..., A. D. MacKerell, Jr. 2017. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. *Nat. Methods*. 14:71–73.

Biophysical Journal, Volume 120

Supplemental information

Modeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape

Genevieve Kunkel, Mohammad Madani, Simon J. White, Paulo H. Verardi, and Anna Tarakanova

Supplementary Information

Modeling Coronavirus Spike Protein Dynamics: Implications for Immunogenicity and Immune Escape

G. Kunkel¹, M. Madani¹, S. J. White², P. H. Verardi³, A. Tarakanova^{1,4*}

1. Department of Mechanical Engineering, University of Connecticut, Storrs, CT, USA

2. Department of Molecular and Cell Biology, University of Connecticut, Storrs, CT, USA

3. Department of Pathobiology and Veterinary Science, University of Connecticut, Storrs, CT, USA

4. Department of Biomedical Engineering, University of Connecticut, Storrs, CT, USA

* Corresponding author: anna.tarakanova@uconn.edu

1. SARS-CoV-2 Protein Sequences

*Mutations are in yellow

** Spike protein names correspond to what is listed in the literature through experimental studies or by database identifier. If no name exists, then the spike protein mutant is assigned a name. For proteins that are assigned a name, the naming conventions of its associated experimental study are used. If this information is not listed, then different families of mutations are separated by a period and mutation is assigned a numerical identifier. For example, the 6VXX SARS-CoV-2 mutant sequence contains a signal peptide and trimerization motif, thus its name convention is SC2.S1.TM1. Should another spike protein have the same, for example, trimerization motif mutation, it will also have the “.TM1” identifier. Similar families of mutations include dashes.

Uniport P0DTC2 (Wild Type Sequence)

MFVFLVLLPLVSSQCVNLTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSG
TNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDLSDKTSLLIVNNAATNVVIKVCDFQFCNDPFLGVY
YHKNKNSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRD
LPQGFSALEPLVDLPIGINITRFQTLALHRSYLTGPDSSSGWTAGAAAYYVGYLQPRFTLLKYNENGTITD
AVDCALDPLSEKCTLSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCDFGEVFNATRFASVYAWNRKRISN
CVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTG
CVIAWNSNNLDSKVGGNYNLYRFLFRKSNLKPFRDISTEIQAGSTPCNGVEGFNCFYPLQSYGFQPTNG
VGYQPYRVVVLSEFLLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQFGRDIADTT
DAVRDPQTLEILDITPCSFSGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGNSVVFQT
RAGCLIGAEHVNSYECDIPIGAGICASYQTQTNPRRARSVASQSIIAYTMSLGAENSVAYSNNIAIPTNFT
ISVTTEILPVSMTKTSVDCTMYICGDSTECNSLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKT
PPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLCAQKFNGLTVLPPLL
TDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMA YRFNGIGVTQNVLYENQKLIANQFN SAIGKIQD
SLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRDLKVEAEVQIDRLITGRLQSLQTYV
TQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLM SFPQSAPHGVVFLHVTVVPAQEKNF TTA
PAICHDGKAHFPREGVVFVSNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKE
ELDKYFKNHTSPDVLGDISGINASVNNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIA
GLIAIVMVTIMLCCMTSCCCLKGCSCGSCCKFDEDDSEPVLKGVKLLHYT

Name: BiPro

PDB: 6VSB (2)

MFVFLVLLPLVSSQCVNLTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSG
TNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDLSDKTSLLIVNNAATNVVIKVCDFQFCNDPFLGVY

YHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRD
LPQGFSALEPLVDLPIGINITRFQTLALHRSYLTGDDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITD
AVDCALDPLSEKCTKLSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISN
CVADYSVLYNSASFSTFKCYGVSPTKLNLDLFCFTNVYADSFVIRGDEVQRQIAPGQTGKIADYNYKLPDDFTG
CVIAWNSNNLDSKVGGNYNLYRLFRKSNLKPFRDISTEYIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNG
VGYQPYRVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNGLTGTGVLTESNKKFLPFQFGRDIADTT
DAVRDPQTEILDITPCFSGGVSITPGTNTSNQVAVLYQDVCNCTEVPVAIHADQLTPTWRVYSTGNSVFQT
RAGCLIGAEHVNSYECDIPIGAGICASYQTQTNSPGSASVSVASQSIAYTMSLGAENSVAYSNNNSIAIPTNFT
ISVTTEILPVSMTKTSVDCTMYICGDSSTECNSNLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKT
PPIKDFGGFNFSQILPDPSPKPSKRSFIEDLLFNKVTADAGFIKQYGDCLGDIAARDLCAQKFNGLTVLPPLL
TDEMIAQYTSALLAGTITSGWTFGAGAAALQIPFAMQMA YRFNGIGVTONVLYENQKLIANQFNSAIGKIQD
SLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPEAEVQIDRLITGRLQSLQTYVT
QQLIRAAEIRASANLAATKMSECVLGGSKRVDFCGKGYHLMSPQSAPHGVVFLHVTVYVPAQEKNFTTAP
AICHGKAHFPREGVVFVSNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEE
LDKYFKNHTSPDVLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAY
VRKDG EWVLLSTFLGRSLEVLFGQPGHHHHHHHSAWSHPQFEKGGGSGGGSGGSAWSHPQFEK

Unresolved: 1-26, 67-78, 96-98, 143-155,177-186, 247-260, 330-334, 444-490, 501-502, 621-640, 673-686, 812-814,
829-850, 1147-1288

Name: HexaPro

PDB: 6XKL (3)

MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSG
TNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDLSDKTSLLIVNNAATNVVIKVCDFQFCNDPFLGVY
YHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRD
LPQGFSALEPLVDLPIGINITRFQTLALHRSYLTGDDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITD
AVDCALDPLSEKCTKLSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISN
CVADYSVLYNSASFSTFKCYGVSPTKLNLDLFCFTNVYADSFVIRGDEVQRQIAPGQTGKIADYNYKLPDDFTG
CVIAWNSNNLDSKVGGNYNLYRLFRKSNLKPFRDISTEYIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNG
VGYQPYRVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNGLTGTGVLTESNKKFLPFQFGRDIADTT
DAVRDPQTEILDITPCFSGGVSITPGTNTSNQVAVLYQDVCNCTEVPVAIHADQLTPTWRVYSTGNSVFQT
RAGCLIGAEHVNSYECDIPIGAGICASYQTQTNSPGSASVSVASQSIAYTMSLGAENSVAYSNNNSIAIPTNFT
ISVTTEILPVSMTKTSVDCTMYICGDSSTECNSNLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKT
PPIKDFGGFNFSQILPDPSPKPSKRSPIEDLLFNKVTADAGFIKQYGDCLGDIAARDLCAQKFNGLTVLPPLL
TDEMIAQYTSALLAGTITSGWTFGAGPALQIPPMQMA YRFNGIGVTONVLYENQKLIANQFNSAIGKIQDS
LSSTPSALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPEAEVQIDRLITGRLQSLQTYVTQ
QLIRAAEIRASANLAATKMSECVLGGSKRVDFCGKGYHLMSPQSAPHGVVFLHVTVYVPAQEKNFTTAPAI
CHDGKAHFPREGVVFVSNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELD
KYFKNHTSPDVLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVR
KDG EWVLLSTFLGRSLEVLFGQPGHHHHHHHSAWSHPQFEKGGGSGGGSGGSAWSHPQFEK

Unresolved: 1-26, 67-78, 96-98, 143-155,177-186, 247-260, 330-334, 444-490, 501-502, 621-640, 673-686, 812-814,
829-850, 1147-1288

Name: BiPro-1

PDB: 6Z97 (4)

MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSG
TNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDLSDKTSLLIVNNAATNVVIKVCDFQFCNDPFLGVY
YHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRD
LPQGFSALEPLVDLPIGINITRFQTLALHRSYLTGDDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITD
AVDCALDPLSEKCTKLSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISN
CVADYSVLYNSASFSTFKCYGVSPTKLNLDLFCFTNVYADSFVIRGDEVQRQIAPGQTGKIADYNYKLPDDFTG
CVIAWNSNNLDSKVGGNYNLYRLFRKSNLKPFRDISTEYIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNG
VGYQPYRVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNGLTGTGVLTESNKKFLPFQFGRDIADTT
DAVRDPQTEILDITPCFSGGVSITPGTNTSNQVAVLYQDVCNCTEVPVAIHADQLTPTWRVYSTGNSVFQT
RAGCLIGAEHVNSYECDIPIGAGICASYQTQTNSPGSASVSVASQSIAYTMSLGAENSVAYSNNNSIAIPTNFT

ISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKT
PPIKDFGGFNFSQILPDPSPKSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLCAQKFNGLTVLPPLL
TDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQD
SLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRDLPPAEAVQIDRLITGRLQSLQTYVT
QQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTVYVPAQEKNFHTTAP
AICHGDKAHFPREGVVFVSNNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGVNNTVYDPLQPELDSFKEE
LDKYFKNHTSPDVLDGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQSGSYIPEAPRDGQAY
VRKDG EWVLLSTFLGRSLEVLVFGQPGHHHHHHHHHGS A WSH PQFEKGGGSGGSGGSA WSH PQFEK

Unresolved: 1-26, 70-81,114-115, 144-187, 243-262, 621-640, 677-689, 828-850, 1148-1288

Name: SC2.S1.TM1

PDB: 6VYB & 6VXX (5)

MGILPSPGMPALLSLVSLLSVLLMGCVAETGTQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQ
DLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSTQSLIVNNA
TVVIKVFCEQFCNDPFLGVYVYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFK
NIDGYFKIYSKHTPINLVRDLPOGFSALEPLVDLPIGINITRFQTLALHRSYLT PGDSSSGWTAGAAA YVVG
YLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEV
NATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEV RQIAPG
QTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNLYRFRKSNLKPFRDISTEYIYQAGSTPCNGVE
GFNCYFPLQSYGFQPTNGVGYQPYRVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNGLTGTGVLTE
SNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNEVAVLYQDVNCTEVPVAIHAD
QLTPTWRVYSTGNSVVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPSGAGS VASQSIIAYTMSL
GAENSVAYSNNIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVE
QDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSPKSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAA
RDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY
ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRDLPPAE
AVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVV
FLHVTVYVPAQEKNFHTTAPAICHGDKAHFPREGVVFVSNNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGV
NNTVYDPLQPELDSFKEELDKYFKNHTSPDVLDGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGK
YEQYIKSGRENLYFQGGGGSGYIPEAPRDGQAYVRKDG EWVLLSTFLGHHHHHHHHH

Unresolved: 1-26, 70-81, 114-115, 144-185, 243-262, 443-489, 502, 621-640, 677-689, 812, 828-854, 1148-1281

Name: SC2.S2. TM1-1

PDB: 6ZGG (6)

MGILPSPGMPALLSLVSLLSVLLMGCVAETGMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPD
KVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSTQ
TQSLIVNNA TNVVIKVFCEQFCNDPFLGVYVYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQ
GNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPOGFSALEPLVDLPIGINITRFQTLALHRSYLT PGDSSSG
WTAGAAA YVVG YLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR
FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF
VIRGDEV RQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNLYRFRKSNLKPFRDISTEYI
YQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVLSFELLHAPATVCGPKKSTNLVKNKCVNFN
FNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQD
VNCTEVPVAIHADQLTPTWRVYSTGNSVVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARS
VASQSIIAYTMSLGAENSVAYSNNIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFC
TQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSPKSKRSFIEDLLFNKVTLADAGFI
KQYGDCLGDIAARDLCAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYR
FNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVL
NDILSRDLPPAEAVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHL
MSFPQSAPHGVVFLHVTVYVPAQEKNFHTTAPAICHGDKAHFPREGVVFVSNNGTHWFVTQRNFYEPQIITDNT
FVSGNCDVVIGVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVLDGDISGINASVVNIQKEIDRLNEVAKN
L NESLIDLQELGKYEQSGRENLYFQGGGGSGYIPEAPRDGQAYVRKDG EWVLLSTFLGHHHHHHH

Unresolved: 1-13, 71-75, 618-640, 677-688, 828-848, 941-943, 1147-1287

Name: SC2.N1.C1.2P.TM2

PDB: 6XF6 (7)

GPQCVNLTRRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNP
VLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLIVNATNVVIKVECFQFCNDPFLGVYYHKNNKSWM
ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEP
LVDLPIGINITRFQTLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLS
ETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLY
NSASFSTFKCYGVSPTKLNLDLFCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNN
LDSKVGGNYNLYRFLFRKSNLKPFERDISTEIQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVV
VLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQFGRDIADTTDAVRDPQTL
EILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGNSVFNQTRAGCLIGAE
HVNNSYECDIPIGAGICASYQTQTNPSGSASVSVASQSIAYTMSLGAENSVAYSNNIAIPTNFTISVTTEILPV
SMTKTSVDCTMYICGDSTECSNLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGF
NFSQILPDPSPKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLCAQKFNGLTVLPPLLDEMIAQY
TSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTVQNVLYENQKLIANQFNSAIGKIQDSLSTASAL
GKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRDPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEI
RASANLAATKMSECVLQSKRVDFCGKGYHLSMFPQSAPHGVVFLHVTVYVPAQEKNTTAPAICHDKGA
HFPREGVFSNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGVNNTVYDPLQPELDSFKEELDKYFKNH
TSPDVLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGW
VLLSTFLGRSGGLVPQQSGGLNDIFEAQKIEWHEG

Unresolved: 12-26, 70-81, 114-115, 144-165, 173-185, 243-262, 621-640, 677-690, 828-854, 1148-1266

Name: SC2.C2. 1P. TM3

PDB: 7AD1 (8)

MFVFLVLLPLVSSQCVNLTRRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSG
TNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLIVNATNVVIKVECFQFCNDPFLGVY
YHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRD
LPQGFSALEPLVDLPIGINITRFQTLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITD
AVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISN
CVADYSVLYNSASFSTFKCYGVSPTKLNLDLFCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTG
CVIAWNSNNLDSKVGGNYNLYRFLFRKSNLKPFERDISTEIQAGSTPCNGVEGFNCYFPLQSYGFQPTNG
VGYQPYRVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQFGRDIADTT
DAVRDPQTLLEILDITPCSFGGVSVITPGTNTSNQVAVLYQNVNCTEVPVAIHADQLTPTWRVYSTGNSVFNQ
RAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNPSRAGSVSVASQSIAYTMSLGAENSVAYSNNIAIPTNFT
ISVTTEILPVSMKTSVDCTMYICGDSTECSNLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKT
PPIKDFGGFNFSQILPDPSPKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLCAQKFNGLTVLPPLL
DEMIAQYTSALLAGTITSGWTFGAGPALQIPFAMQMAYRFNGIGVTVQNVLYENQKLIANQFNSAIGKIQD
SLSSTPSALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRDPEAEVQIDRLITGRLQSLQTYVT
QQLIRAAEIIRASANLAATKMSECVLQSKRVDFCGKGYHLSMFPQSAPHGVVFLHVTVYVPAQEKNTTAP
AICHDKGAHFPREGVFSNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGVNNTVYDPLQPELDSFKEE
LDKYFKNHTSPDVLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAY
VRKDGWVLLSTFLGRSLEVLFPQPGSLPETGGGSDYKDDDDKGGGGSGGGGGSGGGGGSGGGGGSH
HHHHH

Unresolved: 1-26, 70-87, 114-115, 132-165, 173-185, 243-262, 443-448, 477-489, 502-503, 621-640, 677-689, 812,
828-854, 1148-1297

Name: u1S2q

PDB: 6X2B (9)

VNLTRRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFN
DGVYFASTEKSNIIRGWIFGTTLDSKTQSLIVNATNVVIKVECFQFCNDPFLGVYYHKNNKSWMESEFR
VYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPI
GINITRFQTLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTL
KSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFST

FKCYGVSPTKLNLDLCFTNVYADSFVIRGDEVQRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVG
GNYNYLYRLFRKSNLKPFRDISTEIQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVLSFELL
HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDILDITDAVRDPQTLEILDITPC
SFGGVSVITPGTNTSNEVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYE
CDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGAENSVAYSNNNSIAIPTNFTISVTTEILPVSMTKTSV
DCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPD
PSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKYIGLTVLPPLLDEMIAQYTSALLAGT
ITSGWTFGAGAALQIPFAMQMA YRFNGIGVTQNVLYENQKLIANQFN SAIGKIQDLSSTASALGKLQDVV
NQNAQALNTLVKQLSSNF GAISSVLNDILSRDPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLA
ATKMSECVLGQSKRVDFCGKGYHLSFPQSAPHGVVFLHVTVVPAQEKNFTTAPAICHGDKAHFPREGVF
VSNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVLDG
DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWLLSTFLGR
SLEVLFGQPGHHHHHHHSAW SHPQFEKGGGSGGGGSSGSAW SHPQFEK

Unresolved: 16-26, 68-81, 114-115, 144-185, 243-262, 443-489, 502, 621-640, 677-689, 812, 828-854, 1148-1288

Name: SC2.C1. 2P

PDB: 7CN9 (10)

QCVNLTTRTQLPPAYTNSFTRGVVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLP
FNDGVYFASTEKSNIIRGWIFGTTLD SKTQSLIVN NATNVVIK VCEFCNDPFLGVYYHKNNKSWMESEF
RVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYKHTPINLVRDLPQGFSALEPLVDL
PIGINITRFQTLALHRSYLT PGDSSSGWTAGAAA YVGYLQPR TFLLYNENGTITDAVDCALDPLSETKC
TLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLVNSASF
STFKCYGVSPTKLNLDLCFTNVYADSFVIRGDEVQRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKV
GGNYNYLYRLFRKSNLKPFRDISTEIQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVLSFEL
LHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP
CSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSY
ECDIPIGAGICASYQTQTNSPGSAGSVASQSIIAYTMSLGAENSVAYSNNNSIAIPTNFTISVTTEILPVSMTKTS
VDCTMYICGDSTEC SNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILP
DPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLDEMIAQYTSALLA
GTITSGWTFGAGAALQIPFAMQMA YRFNGIGVTQNVLYENQKLIANQFN SAIGKIQDLSSTASALGKLQD
VVNQNAQALNTLVKQLSSNF GAISSVLNDILSRDPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASAN
LAATKMSECVLGQSKRVDFCGKGYHLSFPQSAPHGVVFLHVTVVPAQEKNFTTAPAICHGDKAHFPREG
VFVSNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGIVNNTVYDP

Unresolved: 14-26, 180-182, 444-489, 622-640, 673-685, 812-852

Name: SC2.C1.2P.TM4

PDB: 6XM0 (11)

QCVNLTTRTQLPPAYTNSFTRGVVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLP
FNDGVYFASTEKSNIIRGWIFGTTLD SKTQSLIVN NATNVVIK VCEFCNDPFLGVYYHKNNKSWMESEF
RVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYKHTPINLVRDLPQGFSALEPLVDL
PIGINITRFQTLALHRSYLT PGDSSSGWTAGAAA YVGYLQPR TFLLYNENGTITDAVDCALDPLSETKC
TLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLVNSASF
STFKCYGVSPTKLNLDLCFTNVYADSFVIRGDEVQRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKV
GGNYNYLYRLFRKSNLKPFRDISTEIQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVLSFEL
LHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITP
CSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSY
ECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGAENSVAYSNNNSIAIPTNFTISVTTEILPVSMTKTS
VDCTMYICGDSTEC SNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILP
DPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLDEMIAQYTSALLA
GTITSGWTFGAGAALQIPFAMQMA YRFNGIGVTQNVLYENQKLIANQFN SAIGKIQDLSSTASALGKLQD
VVNQNAQALNTLVKQLSSNF GAISSVLNDILSRDPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASAN
LAATKMSECVLGQSKRVDFCGKGYHLSFPQSAPHGVVFLHVTVVPAQEKNFTTAPAICHGDKAHFPREG
VFVSNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVLD

LGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQ **GSgyIPEAPRDGQAYVRKDGewVLLSTFLGRSLEVLfQGPgHHHHHHHSAWSHPQFEKGGGSGGGGSGGSAWSHPQFEK**

Unresolved: 14-26, 70-79, 144-158, 174-185, 251-263, 445-446, 677-688, 829-848, 1148-1288

Name: SC2. TM4-1

PDB: 6XR8 (12)

MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSG
TNGTKRFDNPVLPFNDGVYFASTEKSNIRGWIFGTTLDLSDKTSLLIVNNAATNVVIKVCDFQFCNDPFLGVY
YHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRD
LPQGFSALEPLVDLPIGINITRFQTLALHRSYLT PGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITD
AVDCALDPLSETKCTLSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYA WNRKRISN
CVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVQRQIAPGQTGKIADYNYKLPDDFTG
CVIAWNSNNLDSKVGGNYNLYRFRKSNLKPFERDISTEIQAGSTPCNGVEGFNCFYPLQSYGFQPTNG
VGYQPYRVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQFGRDIADTT
DAVRDPQTL EILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGNSVFPQT
RAGCLIGAEHVNSYECDIPIGAGICASYQTQNSP RRARSVASQSIIAYTMSLGAENSVAYSNNNSIAIPTNFT
ISVTTEILPVSMTKTSVDCTMYICGDSTEC SNLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKT
PPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPLL
TDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMA YRFNGIGV TQNVLYENQKLIANQFN SAIGKIQD
SLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRDLKVEAEVQIDRLITGRLQSLQTYV
TQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLSFPQSAPHGVVFLHVTVYVPAQEKNTTAP
AICHHDGKAHFPREGV FVSNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKE
ELDKYFKNHTSPD VDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIA
GLIAIVMVTIMLCCMTSCCCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT **LESGGGSAWSHPQFEKGGGS
GGGSGSSAWSHPQFEK**

Name: SC2.C1. 2P. TM4-2

PDB: 6XM4 (11)

QCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLP
FNDGVYFASTEKSNIRGWIFGTTLDLSDKTSLLIVNNAATNVVIKVCDFQFCNDPFLGVYYHKNNKSWMESEF
RVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDL
PIGINITRFQTLALHRSYLT PGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKC
TLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYA WNRKRISNCVADYSVLYNSASF
STFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVQRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKV
GGNYNLYRFRKSNLKPFERDISTEIQAGSTPCNGVEGFNCFYPLQSYGFQPTNGVGYQPYRVVLSFEL
LHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQFGRDIADTTDAVRDPQTL EILDITP
CSFGGVS VITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGNSVFPQTRAGCLIGAEHVNSY
ECDIPIGAGICASYQTQNSP **GSAS**SVASQSIIAYTMSLGAENSVAYSNNNSIAIPTNFTISVTTEILPVSMTKTS
VDCTMYICGDSTEC SNLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILP
DPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPLL TDEMIAQYTSALLA
GTITSGWTFGAGAALQIPFAMQMA YRFNGIGV TQNVLYENQKLIANQFN SAIGKIQDLSSTASALGKLQD
VVNNAQALNTLVKQLSSNFGAISSVLNDILSRDL **PPE**AEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASAN
LAATKMSECVLGQSKRVDFCGKGYHLSFPQSAPHGVVFLHVTVYVPAQEKNTTAP AICHHDGKAHFPREG
V FVSNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPD V
LGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQ **GSgyIPEARDGQAYVRKDGewVLLSTFLGRSLEVLfQGPgHHHHHHHSAWSHPQFEKGGGSGGGGSGGSAWSHPQFEK**

Unresolved: 14-26, 70-79, 144-185, 251-263, 445-446, 677-688, 829-848, 1148-1288

Name: SC2.C1.TM4-2

PDB: 7KDH (13)

MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSG
TNGTKRFDNPVLPFNDGVYFASTEKSNIRGWIFGTTLDLSDKTSLLIVNNAATNVVIKVCDFQFCNDPFLGVY
YHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRD

LPQGFSALEPLVDLPIGINITRFQTLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITD
AVDCALDPLSETKCTLKSTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYA WNRKRISN
CVADYSVLYNSASFSTFKCYGVSPTKLNLDL CFTNVYADSFVIRGDEVQRQIAPGQTGKIADYNYKLPDDFTG
CVIAWNSNNLDSKVGGNYNLYRLFRKSNLKPFERDISTEYQAGSTPCNGVEGFNCYFPLQSYGFQPTNG
VGYQPYRVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQFGRDIADTT
DAVRDPQTEILDITPCSFSGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGNSVNFQT
RAGCLIGAEHVNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGAENSVAYSNNNSIAIPTNFT
ISVTTEILPVSMTKTSVDCTMYICGDSSTECNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKT
PPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPLL
TDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMA YRFNGIGVTONVLYENQKLIANQFN SAIGKIQD
SLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRDLKVEAEVQIDRLITGRLQSLQTYV
TQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLM SFPQSAPHGVVFLHVTVYVPAQEKNFTTA
PAICHGKAHFPRGVFVSNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKE
ELDKYFKNHTSPDVLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQ GSGYIPEAPRDGQA
YVRKDG EWVLLSTFLGRSLEVLFGQPGHHHHHHHSA WSHPOFEKGGGSGGGGSSGSA WSHPOFEK

Unresolved: 1-26, 70-81, 144-185, 243-262, 443-447, 471-489, 502, 621-640, 677-689, 812-852, 1148-1288

Name: BiPro-0

PDB: 6ZP7 (14)

MFVFLVLLPLVSSQCVNLTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSG
TNGTKRFDNPVLPFNDGVYFASTSEKSNIRGWIFGTTLD SKTQSLIVN NATNVVIK VCEFCNDPFLGVY
YHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLE GKQGNFKNLREFVFKNIDGYFKIYSKHTPINLV RD
LPQGFSALEPLVDLPIGINITRFQTLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITD
AVDCALDPLSETKCTLKSTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYA WNRKRISN
CVADYSVLYNSASFSTFKCYGVSPTKLNLDL CFTNVYADSFVIRGDEVQRQIAPGQTGKIADYNYKLPDDFTG
CVIAWNSNNLDSKVGGNYNLYRLFRKSNLKPFERDISTEYQAGSTPCNGVEGFNCYFPLQSYGFQPTNG
VGYQPYRVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQFGRDIADTT
DAVRDPQTEILDITPCSFSGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGNSVNFQT
RAGCLIGAEHVNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNNSIAIPTNFT
ISVTTEILPVSMTKTSVDCTMYICGDSSTECNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKT
PPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPLL
TDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMA YRFNGIGVTONVLYENQKLIANQFN SAIGKIQD
SLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRDLPEAEVQIDRLITGRLQSLQTYVT
QQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLM SFPQSAPHGVVFLHVTVYVPAQEKNFTTAP
AICHGKAHFPRGVFVSNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEE
LDKYFKNHTSPDVLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIA G
LIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPV LKGVKLHYT

Unresolved: 40-53, 105-134, 147-160, 216-234, 419-420, 594-612, 650-661, 802-824, 1122-1273

Name: SC2.TM5

PDB ID: 7C2L (35)

MFVFLVLLPLVSSQCVNLTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSG
TNGTKRFDNPVLPFNDGVYFASTSEKSNIRGWIFGTTLD SKTQSLIVN NATNVVIK VCEFCNDPFLGVY
YHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLE GKQGNFKNLREFVFKNIDGYFKIYSKHTPINLV RD
LPQGFSALEPLVDLPIGINITRFQTLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITD
AVDCALDPLSETKCTLKSTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYA WNRKRISN
CVADYSVLYNSASFSTFKCYGVSPTKLNLDL CFTNVYADSFVIRGDEVQRQIAPGQTGKIADYNYKLPDDFTG
CVIAWNSNNLDSKVGGNYNLYRLFRKSNLKPFERDISTEYQAGSTPCNGVEGFNCYFPLQSYGFQPTNG
VGYQPYRVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQFGRDIADTT
DAVRDPQTEILDITPCSFSGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGNSVNFQT
RAGCLIGAEHVNSYECDIPIGAGICASYQTQTN SPRGSASSVASQSIIAYTMSLGAENSVAYSNNNSIAIPTNF
TISVTTEILPVSMTKTSVDCTMYICGDSSTECNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYK
TPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPLL
LTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMA YRFNGIGVTONVLYENQKLIANQFN SAIGKIQ

DSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTY
VTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTVYVPAQEKNF
APAICHDGKAHFPREGVVFVSNNGTHWFVTQRNFYEPQIITDNTFVSGNCDVVIGVNNNTVYDPLQPELDSFK
EELDKYFKNHTSPDVLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGF
AGLIAIVMVTIMLCCMTSCCCLKGCCSCGSCCKFDEDDSEPVKGVKLVHT**L**EDYKDDDDK

2. SARS-CoV Protein Sequences

SARS-CoV WT (Uniprot ID P59594) (15)

MFIFLLFLTSTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTIN
HTFGNPVPIPKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFAVSKPMG
TQHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFNKNDGFLYVYKGYQPIDVVRDLPSGFNTLK
PIFKLPLGINITNFRAILTAFAAQAQDIWGTSAAYFVGYLKPTTFMLKYDENGTTIDA VDCSQNPLAELKCSV
KSFEIDKGIYQTSNFRVVPDGDVVRFPNITNLCPFGEVFNATKFPVYAWERKKISNCVADYSVLNSTFFST
FKCYGVSATKLNLDLFCFSNVYADSFVVKGDDVQRQIAPGQTGVADYNYKLPDDFMGCVLAWNTRNIDATS
TGNVNYKYRYLRHGKLRPFERDISNVFPDGPCTPPALNCYWPLNDYGFYTTTGIGYQPYRVVLSFEL
LNAPATVCGPKLSTDLIKNQCVNFNENGLTGTGVLTPSSKRFQPFQFGRDVSDFDTSVRDPKTSEILDISP
SFGGVSVITPGTNASSEVAVLYQDVNCTDVSTAIHADQLTPAWRIYSTGNNVFQTQAGCLIGAHEVDTSYE
CDIPIGAGICASYHTVSLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCN
MYICGDSTECANLLLQYGSFCTQLNRLSGIAAEQDRNTREVFAQVKQMYKTPTLKYFGGFNFSQILPDPL
KPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLCAQKFNGLTVLPPLLTDMMIAAYTAALVSGT
ATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAIQIQESLTTTSTALGKLQDV
VNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL
AATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTVYVPSQERNFTTAPAICHEGKAYFPREGV
FVFNGTSWFITQRNFSPQIITDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVLG
DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGFIAGLIAIVMVTILLCCMTS
CCSCLKGACSCGSCCKFDEDDSEPVKGVKLVHT

Name: SC1. TM1

PDB: 6ACD (35)

MFIFLLFLTSTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTIN
HTFGNPVPIPKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFAVSKPMG
TQHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFNKNDGFLYVYKGYQPIDVVRDLPSGFNTLK
PIFKLPLGINITNFRAILTAFAAQAQDIWGTSAAYFVGYLKPTTFMLKYDENGTTIDA VDCSQNPLAELKCSV
KSFEIDKGIYQTSNFRVVPDGDVVRFPNITNLCPFGEVFNATKFPVYAWERKKISNCVADYSVLNSTFFST
FKCYGVSATKLNLDLFCFSNVYADSFVVKGDDVQRQIAPGQTGVADYNYKLPDDFMGCVLAWNTRNIDATS
TGNVNYKYRYLRHGKLRPFERDISNVFPDGPCTPPALNCYWPLNDYGFYTTTGIGYQPYRVVLSFEL
LNAPATVCGPKLSTDLIKNQCVNFNENGLTGTGVLTPSSKRFQPFQFGRDVSDFDTSVRDPKTSEILDISP
SFGGVSVITPGTNASSEVAVLYQDVNCTDVSTAIHADQLTPAWRIYSTGNNVFQTQAGCLIGAHEVDTSYE
CDIPIGAGICASYHTVSLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCN
MYICGDSTECANLLLQYGSFCTQLNRLSGIAAEQDRNTREVFAQVKQMYKTPTLKYFGGFNFSQILPDPL
KPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLCAQKFNGLTVLPPLLTDMMIAAYTAALVSGT
ATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAIQIQESLTTTSTALGKLQDV
VNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL
AATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTVYVPSQERNFTTAPAICHEGKAYFPREGV
FVFNGTSWFITQRNFSPQIITDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVLG
DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWSHPQFEK

Name: SC1.S1.TM2

PDB: 6NB6 (35)

MGILPSPGMPALLSLVLLSVLLMGCVAETGTSDDLDRCTTFDDVQAPNYTQHTSSMRGVVYYPDEIFRSDTL
YLTQDLFLPFYSNVTGFHTINHTFDNPIPKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVI
RACNFELCDNPFFAVSKPMGTQHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFNKNDGFLYV
YKGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFAAQAQDTWGTSAAYFVGYLKPTTFMLKYDE
NGTTIDA VDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPDGDVVRFPNITNLCPFGEVFNATKFPVYAW

ERKKISNCVADYSVLYNSTFFSTFKCYGVSATKLNLCFSNVYADSFVVKGDDVVRQIAPGQTGVIADYNYK
LPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCPPALNCYWPLNDY
GFYTTTGIGYQPYRVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNGLTGTGVLTPSSKRFPFQFGR
DVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASSEVAVLVYQDVNCTDVSTAIHADQLTPAWRIYSTGN
NVFQTQAGCLIGAHEVDTSECDIPIGAGICASYHTVSLLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNF
SISITTEVMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSGLAAEQDRNTREVFAQVKQMY
KTPTLKYFGGFNFSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVL
PPLLTDDMIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAI
SQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLDILSRLDPPEAEVQIDRLITGRLQSL
QTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLSMFPQAAPHGVVFLHVTVVPSQERN
FTTAPAICHEGKAYFPREGVVFVNGTSWFITQRNFFSPQIITDNTFVSGNCDVVIGIINNTVYDPLQPELDSF
KEELDKYFKNHTSPDVLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEYQYKGSRENLYF
QGGGGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGHHHHHHHH

3. MERS-CoV Protein Sequences

MERS-CoV WT (Uniprot ID K9N5Q8) (16)

MIHSVFLLMFLLTPTESYVDVGPDSVKSACIEVDIQQTFDFKTWPRPIDVSKADGHIYPQGRITYSNITITYQGL
FPYQGDHGDYMYVYSAGHATGTTTPQKLFVANYSQDVKQFANGFVVRIGAAANSTGTVIISPSTSATIRKIYP
AFMLGSSVGNFSDGKMGRRFNHTLVLLPDGCGTLLRAFYCILEPRSGNHCPAGNSYTSFATYHTPATDCSD
GNYNRNASLNSFKEYFNLRNCTFMYTYNITEDEILEWFGITQTAQGVHLFSSRYVDLYGGNMFQFATLPVY
DTIKYYSIIPHSIRSIQSDRKAWAIFYVYKQLPLTFLDFSVDGYIRRAIDCGFNDSLHCSYESFDVESGV
YSVSSFEAKPSGSVVEQAEGVECDFSPLLSGTPPQVYNFKRLVFTNCNYNLTKLLSLFSVNDFTCSQISPAAI
ASNCYSSLILDYFSYPLSMKSDLSVSSAGPISQFNKQSFNSPTCLILATVPHNLTTITKPLKYSYINKCSRFLS
DDRTEVPQLVNANQYSPCVSIVPSTVWEDGDYRQKLSPLEGGGWLVASGSTVAMTEQLQMFGGITVQY
GTDNNSVCPKLEFANDTKIASQLGNCVEYSLYGVSGRGVFNQCTAVGVRQQRVYDAYQNLVGYSSDDG
NYYCLRACVSPVSVIYDKETKTHATLFGSVACEHISSTMSQYSRSTRSMLKRRDSTYGPLQTPVGCVLGL
VNSSLFVEDCKLPLGQSLCALPDTPTLTPRSVRSVPGEMRLASIAFNHPIQVDQLNSSFYKLSIPTNSFGVTQ
EYIQTTIQKVTVDCKQYVCNGFQKCEQLLREYGFQFCSKINQALHGANLRQDDSVRNLFASVKSSQSSPIIPG
FGGDFNLTLLEPVSISTGSRARSARSAIEDLLFDKVTIADPGYMQGYDDCMQQGPASARDLICAQYVAGYKVL
PPLMDVNMEAAAYTSSLLGSIAGVGTAGLSSFAAIPFAQSIFYRLNGVGITQQVLSNQKLIANKFNQALGA
MQTGFTTTNEAFHKVQDAVNNNAQALSKLASELSNTFGAISASIGDIIQRDLVLEQDAQIDRLINGRLTTLN
AFVAQQLVRSESAALSAQLAKDKVNECVKAQSKRSGFCGQGTHIVSFVVPNAPNGLYFMHVGYYPSNHIEV
VSAYGLCDAANPTNCIAPVNGYFIKTNNTRIVDEWYSYTGSSFYAPEPITSLNTKYVAPQVTYQNIQNLPPPL
LGNSTGIDFQDELDEFFKNVSTIPNFGSLTQINTLLDLTYEMLSLQVVKALNESYIDLKELGNYYTYNK
WPWYIWLGFIAGLVALALCVFFILCCTGCGTNCMGK
LKCNRCCDRYEEYDLEPHKVHVH

Name: MC. SD. TM1

PDB: 5X5C & 5X5F (36)

YVDVGPDSVKSACIEVDIQQTFDFKTWPRPIDVSKADGHIYPQGRITYSNITITYQGLFPYQGDHGDYMYVYS
GHATGTTTPQKLFVANYSQDVKQFANGFVVRIGAAANSTGTVIISPSTSATIRKIYPAFMLGSSVGNFSDGK
MGRRFNHTLVLLPDGCGTLLRAFYCILEPRSGNHCPAGNSYTSFATYHTPATDCSDGNYNRNASLNSFKEYF
NLRNCTFMYTYNITEDEILEWFGITQTAQGVHLFSSRYVDLYGGNMFQFATLPVYDTIKYYSIIPHSIRSIQ
SDRKAWAIFYVYKQLPLTFLDFSVDGYIRRAIDCGFNDSLHCSYESFDVESGVYSVSSFEAKPSGSVVE
QAEGVECDFSPLLSGTPPQVYNFKRLVFTNCNYNLTKLLSLFSVNDFTCSQISPAAIASNCYSSLILDYFSYPL
SMKSDLSVSSAGPISQFNKQSFNSPTCLILATVPHNLTTITKPLKYSYINKCSRLLSDDRTEVPQLVNANQY
SPCVSIVPSTVWEDGDYRQKLSPLEGGGWLVASGSTVAMTEQLQMFGGITVQYGTDNNSVCPKLEFAND
TKIASQLGNCVEYSLYGVSGRGVFNQCTAVGVRQQRVYDAYQNLVGYSSDDGNYYCLRACVSPVSVI
YDKETKTHATLFGSVACEHISSTMSQYSRSTRSMLKRRDSTYGPLQTPVGCVLGLVNSSLFVEDCKLPLGQ
SLCALPDTPTLTPRSVSSVPGEMRLASIAFNHPIQVDQLNSSFYKLSIPTNSFGVTQEYIQTTIQKVTVDCK
QYVCNGFQKCEQLLREYGFQFCSKINQALHGANLRQDDSVRNLFASVKSSQSSPIIPGFGGDFNLTLLEPVSIS
TGSRARSARSAIEDLLFDKVTIADPGYMQGYDDCMQQGPASARDLICAQYVAGYKVLPLMDVNMEAAAYTS
SLLGSIAGVGTAGLSSFAAIPFAQSIFYRLNGVGITQQVLSNQKLIANKFNQALGAMQTGFTTTNEAFQK
VQDAVNNNAQALSKLASELSNTFGAISASIGDIIQRDLVLEQDAQIDRLINGRLTTLNAFVAQQLVRSESA

LSAQLAKDKVNECVKAQSKRSGFCGQGTHIVSFVVNAPNGLYFMHVGYYPSNHIEVVSAYGLCDAANPT
NCIAPVNGYFIKTNTRIVDEWSYTGSSFYAPEPITSLNTKYVAPQVTYQNISTNLPPLLGNSTGIDFQDEL
EFFKNVSTSIPNFGSLTQINTLLDLTYEMLSLQQVVKALNESYIDLKELGNYTYYNK **EFRLVPRGSPGSGYI**
PEAPRDGQAYVRKDG EWVLLSTFLGHHHHH

Name: MC.TM2

PDB: 5W9K (37)

MIHSVFLLMFLLTPTESYVDVGPDSVKSACIEVDIQQTFDFKTWPRPIDVSKADGIIYPQGRYTSNITITYQGL
FPYQGDHGDYVYSAGHATGTTTPQKLFVANYSQDVKQFANGFVVRIGAAAANSTGTVIIISPSTSATIRKIYP
AFMLGSSVGNFSDGKMGRFFNHTLVLLPDGCGTLLRAFYCILEPRSGNHCPAGNSYTSFATYHTPATDCSD
GNYNRNASLNSFKEYFNLRNCTFMYTYNITEDEILEWFGITQTAQGVHLFSSRYVDLYGGNMFFQFATLPVY
DTIKYYSIIPHRSIRSIQSDRKA WAAFYVYKQLPLTFLDFSVLDGYIRRAIDCGFNDLSQLHCSYESFDVESGV
YSVSSFEAKPSGSVVEQAEGVECDFSPLLSGTPPVYVNFKRLVFTNCNYNLTKLLSLSVNDFTCSQISPAAI
ASNCYSSLILDYFSYPLSMKSDLSVSSAGPISQFNKQSFNSPTCLILATVPHNLTTITKPLKYSYINKCSRFLS
DDRTEVPQLVNANQYSPCVSIVPSTVWEDGDYRQKLSPLEGGGWLVASGSTVAMTEQLQMGFGITVQY
GTDNTSVCPLKLEFANDTKIASQLGNCVEYSLYGVSGRGVFNQCTAVGVRRQRFVYDAYQNLVGYYSDDG
NYYCLRACVSVPVSIYDKETKTHATLFGSVACEHISSTMSQYSRSTRSMKRRDSTYGPLQTPVGCVLGL
VNSSLFVEDCKPLGQSLCALPDTPSTLTPASVGSVPGEMRLASIAFNHPIQVDQLNSSFYKLSIPTNFSFGVT
QEYIQTTIQKVTVDCKQYVCNGFQKCEQLLREYGFCSKINQALHGANLRQDDSVRNLFASVKSSQSSPIIP
GFGGDFNLTLEPVSISSGSRARSIAIEDLLFDKVTIADPGYMQGYDDCMQQGPASARDLCAQYVAGYKV
LPPLMDVNMEAAYTSSLLGSIAGVGTAGLSSFAAIPFAQSIFYRLNGVGITQQVLSQKLIANKFNQALG
AMQTGFTTTNEAFHKVQDAVNNAQALSCLASELSNTFGAISASIGDIIQRLDPPEQDAQIDRLINGRLTTL
NAFVAQQLVRSESAALSAQLAKDKVNECVKAQSKRSGFCGQGTHIVSFVVNAPNGLYFMHVGYYPSNHIE
VVSAYGLCDAANPTNCIAPVNGYFIKTNTRIVDEWSYTGSSFYAPEPITSLNTKYVAPQVTYQNISTNLPPP
LLGNSTGIDFQDELDEFFKNVSTSIPNFGSLTQINTLLDLTYEMLSLQQVVKALNESYIDLKELGNYTY **GSG**
YIPEAPRDGQAYVRKDG EWVLLSTFLGRSLEVLFO

4. Supplementary Table 1

See attached file titled [Supplementary Table 1.xlsx](#) for extensive review of individual binding properties and epitopes of over 40 antibodies and their related pdb identifiers. References for the table are located in this document.

5. Protein sequence alignment and comparison

Multiple sequence alignment of spike protein sequences are attached in file [Spike_Protein_Alignment_Tarakanova.clustal_num](#)

6. Dynamic domain & NMA videos

Like the Dynamic Domain index files, videos showing the NMA trajectory and highlighted dynamic domains are labeled [PDB ID].mp4

7. Results of artificial controls

The graphical results of the artificial controls used in **Results section 3.4** are listed below:


i. SC2.S2.TM1-1' & WT'-A

Combined Unresolved regions (WT'A):- 1-26, 70-81, 114-115, 144-185, 243-262, 443-489, 502, 621-640, 677-689, 812, 828-854, 1148-end

Combined unresolved regions (SC2.S2.TM1-1'): 1-26, 70-81,114-115,144-185,243-262, 443-489,502,618-640, 677-698, 812, 828-859, 1148-end

ii. **SC2.C1.2P' & SC2.C1.2P.TM4'**,

Combined unresolved regions:12-26, 70-81, 114-115, 144-165, 173-185, 243-263, 445-446, 621-640, 613-640, 673-690, 812-854, 1148-end



SI Figure 1: The domain dynamics associated with (A) WT'A, (B) SC2.S2.TM1-1', (C) SC2.C1.2P' and (D) SC2.C1.2P.TM4' ANMs. The PDB ID, global dynamics score (GDS), local dynamics scores (LDSs), deformation profile (ii), and Δ SASA profile (iii) is listed for each structure. On each 3-D structure and profile, identified dynamic domains are labeled in different colors and their LDSs are listed in each legend. The corresponding dynamic domain breakdowns are located in Figure 4 and Figure 1.

8. Derived features used for thermal stability model training

The features used to train the thermal stability predictor are those contained in the original combined data set and also those computed by the following resources. The Amber software (39) was used to find bond length, bond angle, dihedral angles, van der Waals contributions, electrostatic contributions, polar solvation, total gas free energy, total solvation free energy, and total system energy. The FoldX software (40) was used to find solvation energy for polar groups, solvation energy for apolar groups, water bridge hydrogen bonding, intra-molecule hydrogen bonding, electrostatic interactions between charged

groups, and atomic clash overlaps. The remaining features are outlined in **Table S3**. Amino acid-related biological features are found using AAindex (42). Disorder and Relative Surface Accessibility are found using the SCRATCH webserver (43). All remaining features in **Table S3** are found using the Expsy ProtScale tool (41).


Table S3: Summary of the biochemical, structural, and biological features used for thermal stability predictor training.

| Biochemical Features | Structural features | Biological Features |
|--|---|-----------------------------|
| Molecular Weight | Solvent Accessibility | Mobility of Amino Acids |
| Hydrophobicity Index | 3-State Secondary Structure | Codon Amount per Amino Acid |
| Side Chain pKa | Bulkiness | |
| Frequencies of buried and exposed sequence | Buried Area from Standard to Folded State | |
| Electrostatic Charge | Disorder | |
| | Flexibility Index | |
| | Relative Surface Accessibility | |
| | Absolute Surface Accessibility | |

9. Analysis of different PDB structures corresponding to a single sequence

i. Statistical threshold model from PDB structures


To resolve whether ANM models can accurately capture differences in dynamic behavior between proteins of different sequence, we selected multiple structures from the PDB that correspond to the same sequence to analyze the correlation between protein structure alignment and the difference in their dynamical signature. We measure the difference between dynamical signatures by the average difference and standard deviation between per-residue protein deformations computed from the ANM-derived trajectory. We explore different levels of protein structural alignment to establish a threshold for measured structural alignment and dynamical similarity. This allows us to evaluate if compared protein structures (see **Results Section 3.4**) experience changes that can in fact be attributed to sequence, or are artifacts of the ANM model. The PDBs used as case studies are listed in **Supplementary Table 2** (see attached file [Supplementary_Table_2.xlsx](#)) and this information is summarized in **Figure 3**. Taken together, the results from the PDB case studies establish a model that describes how NMA dynamics should differ between structures of the same sequence as the structural alignment between compared PDBs differs. Linear regression is used to fit the correlated data to a best fit line, then to calculate the corresponding 95% confidence interval and prediction interval (**SI Figure 2-B**). The prediction interval indicates an estimate of an interval in which a future observation will fall and the confidence interval indicates a range of values that is likely to contain the true mean of the population. From this model, we can understand if the dynamical differences measured between two compared proteins with different sequences are likely to be driven by sequence differences or structural differences (i.e. model artifacts). Data points that fall above the best fit line may attribute their dynamical differences to sequence. Data points below the best fit line indicate that dynamical difference may be an artifact of the model.



SI Figure 2: Proteins selected for a single case study **(A)**, visualization of their structural alignment **(i)** and alignment of their NMA deformations **(ii)**. This pair presents high structural alignment and level of dynamics correspondence and creates a single data point that is plotted with the remaining results of the case studies **(B)**. The plot shows the protein deformation trend variability as a function of the static RBD alignment **(B)**. Note that low alignment values indicate better structure correspondence and high alignment values indicate poorer structure correspondence.

ii. Contribution of sequence and structure to mutant dynamic variability

After establishing a model that characterizes the relationship between PDB structural alignment between pairs of structures and their resulting dynamical differences, we can understand the contribution of sequence-driven dynamical changes in mutants versus changes that arise from e.g. experimental processing variability (i.e. model artifacts). To do this, we perform a similar analysis outlined in the previous section with mutant structures and their controls. If these fall below the best fit line then it is likely that the resulting NMA dynamical differences are driven by experimental processing differences and not sequence. However, if data points fall above the best fit line then it is likely that the differences in NMA deformation profiles, as measured by the standard deviation of deformation difference, is due to the structural differences that arise from changes in protein sequence. Using the linear regression model, we calculate the percent difference between the true mutant standard deviation values with the predicted points on the best fit line and the 95% prediction interval ceiling (**SI Figure 3**). We see that all mutant standard deviation values fall at least 30% above the best fit values for the same RBD alignment and fall at least 2% above the prediction interval ceiling. This suggests that all of the results that we see from comparing the dynamics of mutant proteins and their controls (see **Section 3.4**) are due to the structural consequences of protein sequence.



SI Figure 3: Mutant comparisons made to understand contribution of sequence to dynamic variability. **(A)** Full results are listed and **(B)** the standard deviation of the difference between the deformation curves is plotted against RBD structural alignment in reference to the linear regression model from **SI Figure 2-B**. Proteins that are used to study each group of mutations are highlighted in different colors. **Green** represents furin cleavage mutations, **orange** represents NTD mutations, and **purple** represents proline mutations. All proteins comparisons made for the mutant proteins fall well above the best fit line and 95% intervals, see best fit and prediction interval differences **(A)**, indicating that dynamical differences between mutant and control proteins are driven by sequence.

iii. Molecular dynamics simulation of WT structure

a. Simulation Methods


A 100 ns classical molecular dynamics (MD) simulation was performed on the atomistic WT S protein structure resolved by Amaro et al (44). The Amaro structure is missing the first 13 residues, and these were included in the starting structure by way of homology modeling using the Robetta web server (2). The full sequence was modeled using each chain of the WT MD model as a template. Next, the resulting homology chains were aligned with the WT model, and the 13 residues of the homology model were attached to each chain of the WT model. The resulting RBD-up model, termed WT'-B, is used as the input structure for simulation. The MD simulation was carried out using the GROMACS 2019 version MD software (49) and performed on the TACC Stampede2 HPC platform.

We used the CHARMM36m forcefield, which is uniquely suited for flexible proteins and other biomolecular structure (55). For all runs, the protein was simulated in a neutral cubic water box of size 45^3 nm³ using periodic boundary conditions. Prior to the final production run, an energy minimization, NVT equilibration, and NPT equilibration runs were performed. The energy minimization run was conducted using the steepest descent algorithm. The NVT and NPT equilibration runs were both simulated for 100 ps each. During the NVT run, the protein and environment were equilibrated at 300 K using the V-Rescale

thermostat—Berendsen thermostat with velocity rescaling—for temperature coupling (50). Next, during the NPT run, the system was equilibrated at 1 atm using Parrinello-Rahman barostat for pressure coupling (51). The final MD production was run for a time length of 100 ns at 300 K using a 2 femtosecond time step and the same thermostat and barostat that were employed for the equilibration runs. The Particle Mesh Edwald (PME) algorithm (52) is used for long range electrostatics (grid spacing at 1.6) and Verlet (53) algorithm for neighbor searching (short range cutoffs at 1.0). The LINCS algorithm (54) was used to constrain hydrogen and covalent bonds that are explicitly stated in the protein topology.

b. WT Simulation and ANM Results

We explore different configurations of the WT structure in simulation to confirm if different snapshots from an MD trajectory may impact predicted ANM dynamics. We chose 2 frames from the WT'-B simulation, one in which the up RBD is rotated outward compared to the starting structure and one where the RBD is rotated inward—frames 2400 and 152 respectively. These specific structures were chosen due to the RBD orientation and because they exhibit high RMSD measurements (indicating lower structural alignment). We conduct the same analysis as above and the results are compared to the case study model in **SI Figure 2B**. The alignment analysis was conducted three separate times on (1) the full length protein, (2) protein with the commonly unresolved C-terminus tail removed, and (3) protein with additional commonly unresolved regions removed, to make parallels to the results presented in **Figure 2**. Each data point is the result of one of the more rotated RBD structures taken from the WT'-B simulation trajectory compared to the baseline (Amaro et al.) structure, resulting in 6 total data points. The results for the WT'-B analysis are summarized in **SI Figure 4**. In **SI Figure 4-B**, we see that the majority of points fall below the best fit line, consistent with the fact that structural differences drive dynamical changes rather than a change in sequence. There are 2 points resulting from the proteins with regions removed that fall above the best fit line. However, these fall within the expected range of data variability (95% confidence interval) meaning that the reflected NMA dynamics of the MD snapshots correspond well enough to that of the baseline structure. Overall, these results indicate that reliable results are obtained when using the Amaro WT structure, used in all primary WT analysis, given that it is able to capture the dynamics presented in structurally heterogeneous MD snapshots.



SI Figure 4: Visualization of WT'-B MD snapshots as compared to the baseline WT structure (A). The results of the WT alignment analysis are plotted in reference to the linear regression model that is shown in SI Figure 2-B (B). The deformation curves and their resulting alignment measurements are listed (C) for the full structure (i) structure with tail removed (ii) and structure with additional regions removed (iii). These results show that the WT model used in our main analysis is able to capture the dynamic variability that may come from using an alternative MD model.

10. Supplementary Videos

Videos S1-S20 show the NMA trajectory and dynamic domain results for each analyzed spike protein. Table S4 shows the PDB ID of the protein corresponding to each video.

| Video ID | Protein PDB ID |
|----------|----------------|
| S1 | 5W9K |
| S2 | 6NB6 |
| S3 | 6VSB |
| S4 | 6VYB |
| S5 | 6X2B |
| S6 | 6X2C |
| S7 | 6XF6 |
| S8 | 6XKL |
| S9 | 6XM0 |
| S10 | 6XR8 |
| S11 | 6ZGG |
| S12 | 6ZP7 |
| S13 | 7AD1 |

| | |
|-----|------|
| S14 | 7BYR |
| S15 | 7C2L |
| S16 | 7CN9 |
| S17 | 7JW0 |
| S18 | 7K4N |
| S19 | 7K43 |
| S20 | 7KDH |

References

1. Wu, F., S. Zhao, B. Yu, Y.-M. Chen, W. Wang, Z.-G. Song, Y. Hu, Z.-W. Tao, J.-H. Tian, Y.-Y. Pei, M.-L. Yuan, Y.-L. Zhang, F.-H. Dai, Y. Liu, Q.-M. Wang, J.-J. Zheng, L. Xu, E.C. Holmes, and Y.-Z. Zhang. 2020. A new coronavirus associated with human respiratory disease in China. *Nature*. 579:265–269.
2. Wrapp, D., N. Wang, K.S. Corbett, J.A. Goldsmith, C.-L. Hsieh, O. Abiona, B.S. Graham, and J.S. McLellan. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*. 367:1260–1263.
3. Hsieh, C.-L., J.A. Goldsmith, J.M. Schaub, A.M. DiVenere, H.-C. Kuo, K. Javanmardi, K.C. Le, D. Wrapp, A.G.-W. Lee, Y. Liu, C.-W. Chou, P.O. Byrne, C.K. Hjorth, N.V. Johnson, J. Ludes-Meyers, A.W. Nguyen, J. Park, N. Wang, D. Amengor, J.A. Maynard, I.J. Finkelstein, and J.S. McLellan. 2020. Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes. *bioRxiv*. 2020.05.30.125484.
4. Huo, J., Y. Zhao, J. Ren, D. Zhou, H.M.E. Duyvesteyn, H.M. Ginn, L. Carrique, T. Malinauskas, R.R. Ruza, P.N.M. Shah, T.K. Tan, P. Rijal, N. Coombes, K.R. Bewley, J.A. Tree, J. Radecke, N.G. Paterson, P.P. Supasa, J. Mongkolsapaya, G.R. Screaton, M. Carroll, A. Townsend, E.E. Fry, R.J. Owens, and D.I. Stuart. 2020. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. *Cell Host & Microbe*.
5. Walls, A.C., Y.-J. Park, M.A. Tortorici, A. Wall, A.T. McGuire, and D. Veesler. 2020. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*. 181:281–292.e6.
6. Wrobel, A.G., D.J. Benton, P. Xu, C. Roustan, S.R. Martin, P.B. Rosenthal, J.J. Skehel, and S.J. Gamblin. 2020. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. *Nature Structural & Molecular Biology*. 27:763–767.
7. Bank, R.P.D. RCSB PDB - 6XF6: Cryo-EM structure of a biotinylated SARS-CoV-2 spike probe in the prefusion state (1 RBD up). .
8. Juraszek, J., L. Rutten, S. Blokland, P. Bouchier, R. Voorzaat, T. Ritschel, M.J.G. Bakkers, L.L.R. Renault, and J.P.M. Langedijk. 2020. Stabilizing the Closed SARS-CoV-2 Spike Trimer. *bioRxiv*. 2020.07.10.197814.
9. Henderson, R., R.J. Edwards, K. Mansouri, K. Janowska, V. Stalls, S.M.C. Gobeil, M. Kopp, D. Li, R. Parks, A.L. Hsu, M.J. Borgnia, B.F. Haynes, and P. Acharya. 2020. Controlling the SARS-CoV-2 spike glycoprotein conformation. *Nature Structural & Molecular Biology*. 27:925–933.
10. A Carbohydrate-Binding Protein from the Edible Lablab Beans Effectively Blocks the Infections of Influenza Viruses and SARS-CoV-2: Cell Reports. .
11. Zhou, D., H.M.E. Duyvesteyn, C.-P. Chen, C.-G. Huang, T.-H. Chen, S.-R. Shih, Y.-C. Lin, C.-Y. Cheng, S.-H. Cheng, Y.-C. Huang, T.-Y. Lin, C. Ma, J. Huo, L. Carrique, T. Malinauskas, R.R. Ruza, P.N.M. Shah, T.K. Tan, P. Rijal, R.F. Donat, K. Godwin, K.R. Buttigieg, J.A. Tree, J. Radecke, N.G. Paterson, P. Supasa, J. Mongkolsapaya, G.R. Screaton, M.W. Carroll, J. Gilbert-Jaramillo, M.L. Knight, W. James, R.J. Owens, J.H. Naismith, A.R. Townsend, E.E. Fry, Y. Zhao, J. Ren, D.I. Stuart, and K.-Y.A. Huang. 2020. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. *Nature Structural & Molecular Biology*. 27:950–958.
12. Cai, Y., J. Zhang, T. Xiao, H. Peng, S.M. Sterling, R.M. Walsh, S. Rawson, S. Rits-Volloch, and B. Chen. 2020. Distinct conformational states of SARS-CoV-2 spike protein. *Science*. 369:1586–1592.
13. Gobeil, S.M.-C., K. Janowska, S. McDowell, K. Mansouri, R. Parks, K. Manne, V. Stalls, M. Kopp, R. Henderson, R.J. Edwards, B.F. Haynes, and P. Acharya. 2020. D614G mutation alters SARS-CoV-2 spike conformational dynamics and protease cleavage susceptibility at the S1/S2 junction. *bioRxiv*. 2020.10.11.335299.
14. Melero, R., C.O.S. Sorzano, B. Foster, J.-L. Vilas, M. Martínez, R. Marabini, E. Ramírez-Aportela, R. Sanchez-Garcia, D. Herreros, L. del Caño, P. Losana, Y.C. Fonseca-Reyna, P. Conesa, D. Wrapp, P. Chacon, J.S. McLellan, H.D. Tagare, and J.-M. Carazo. 2020. Continuous flexibility analysis of SARS-CoV-2 Spike prefusion structures. *bioRxiv*. 2020.07.08.191072.

15. Rota, P.A., M.S. Oberste, S.S. Monroe, W.A. Nix, R. Campagnoli, J.P. Icenogle, S. Peñaranda, B. Bankamp, K. Maher, M. Chen, S. Tong, A. Tamin, L. Lowe, M. Frace, J.L. DeRisi, Q. Chen, D. Wang, D.D. Erdman, T.C.T. Peret, C. Burns, T.G. Ksiazek, P.E. Rollin, A. Sanchez, S. Liffick, B. Holloway, J. Limor, K. McCaustland, M. Olsen-Rasmussen, R. Fouchier, S. Günther, A.D.M.E. Osterhaus, C. Drosten, M.A. Pallansch, L.J. Anderson, and W.J. Bellini. 2003. Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. *Science*. 300:1394–1399.
16. Bermingham, A., M.A. Chand, C.S. Brown, E. Aarons, C. Tong, C. Langrish, K. Hoschler, K. Brown, M. Galiano, R. Myers, R.G. Pebody, H.K. Green, N.L. Boddington, R. Gopal, N. Price, W. Newsholme, C. Drosten, R.A. Fouchier, and M. Zambon. 2012. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. *Euro Surveill*. 17:20290.
17. Wu, N.C., M. Yuan, H. Liu, C.-C.D. Lee, X. Zhu, S. Bangaru, J.L. Torres, T.G. Caniels, P.J.M. Brouwer, M.J. van Gils, R.W. Sanders, A.B. Ward, and I.A. Wilson. 2020. An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain. *bioRxiv*. 2020.07.26.222232.
18. Liu, L., P. Wang, M.S. Nair, J. Yu, M. Rapp, Q. Wang, Y. Luo, J.F.-W. Chan, V. Sahi, A. Figueroa, X.V. Guo, G. Cerutti, J. Bimela, J. Gorman, T. Zhou, Z. Chen, K.-Y. Yuen, P.D. Kwong, J.G. Sodroski, M.T. Yin, Z. Sheng, Y. Huang, L. Shapiro, and D.D. Ho. 2020. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature*. 584:450–456.
19. Yuan, M., H. Liu, N.C. Wu, C.-C.D. Lee, X. Zhu, F. Zhao, D. Huang, W. Yu, Y. Hua, H. Tien, T.F. Rogers, E. Landais, D. Sok, J.G. Jardine, D.R. Burton, and I.A. Wilson. 2020. Structural basis of a shared antibody response to SARS-CoV-2. *Science*. 369:1119–1123.
20. Cao, Y., B. Su, X. Guo, W. Sun, Y. Deng, L. Bao, Q. Zhu, X. Zhang, Y. Zheng, C. Geng, X. Chai, R. He, X. Li, Q. Lv, H. Zhu, W. Deng, Y. Xu, Y. Wang, L. Qiao, Y. Tan, L. Song, G. Wang, X. Du, N. Gao, J. Liu, J. Xiao, X. Su, Z. Du, Y. Feng, C. Qin, C. Qin, R. Jin, and X.S. Xie. 2020. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. *Cell*. 182:73-84.e16.
21. Barnes, C.O., C.A. Jette, M.E. Abernathy, K.-M.A. Dam, S.R. Esswein, H.B. Gristick, A.G. Malyutin, N.G. Sharaf, K.E. Huey-Tubman, Y.E. Lee, D.F. Robbiani, M.C. Nussenzweig, A.P. West, and P.J. Bjorkman. 2020. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. *Nature*. 1–9.
22. Du, S., Y. Cao, Q. Zhu, P. Yu, F. Qi, G. Wang, X. Du, L. Bao, W. Deng, H. Zhu, J. Liu, J. Nie, Y. Zheng, H. Liang, R. Liu, S. Gong, H. Xu, A. Yisimayi, Q. Lv, B. Wang, R. He, Y. Han, W. Zhao, Y. Bai, Y. Qu, X. Gao, C. Ji, Q. Wang, N. Gao, W. Huang, Y. Wang, X.S. Xie, X. Su, J. Xiao, and C. Qin. 2020. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. *Cell*. 183:1013-1023.e13.
23. Hansen, J., A. Baum, K.E. Pascal, V. Russo, S. Giordano, E. Wloga, B.O. Fulton, Y. Yan, K. Koon, K. Patel, K.M. Chung, A. Hermann, E. Ullman, J. Cruz, A. Rafique, T. Huang, J. Fairhurst, C. Libertiny, M. Malbec, W. Lee, R. Welsh, G. Farr, S. Pennington, D. Deshpande, J. Cheng, A. Watty, P. Bouffard, R. Babb, N. Levenkova, C. Chen, B. Zhang, A.R. Hernandez, K. Saotome, Y. Zhou, M. Franklin, S. Sivapalasingam, D.C. Lye, S. Weston, J. Logue, R. Haupt, M. Frieman, G. Chen, W. Olson, A.J. Murphy, N. Stahl, G.D. Yancopoulos, and C.A. Kyratsous. 2020. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science*. 369:1010–1014.
24. Lv, Z., Y.-Q. Deng, Q. Ye, L. Cao, C.-Y. Sun, C. Fan, W. Huang, S. Sun, Y. Sun, L. Zhu, Q. Chen, N. Wang, J. Nie, Z. Cui, D. Zhu, N. Shaw, X.-F. Li, Q. Li, L. Xie, Y. Wang, Z. Rao, C.-F. Qin, and X. Wang. 2020. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. *Science*. 369:1505–1509.
25. Bank, R.P.D. RCSB PDB - 6ZHD: H11-H4 bound to Spike. .
26. Tortorici, M.A., M. Beltramello, F.A. Lempp, D. Pinto, H.V. Dang, L.E. Rosen, M. McCallum, J. Bowen, A. Minola, S. Jaconi, F. Zatta, A. De Marco, B. Guarino, S. Bianchi, E.J. Lauron, H. Tucker, J. Zhou, A. Peter, C. Havenar-Daughton, J.A. Wojcechowskyj, J.B. Case, R.E. Chen, H. Kaiser, M. Montiel-Ruiz, M. Meury, N. Czudnochowski, R. Spreafico, J. Dillen, C. Ng, N. Sprugasci, K. Culap, F. Benigni, R.

- Abdelnabi, S.-Y.C. Foo, M.A. Schmid, E. Cameroni, A. Riva, A. Gabrieli, M. Galli, M.S. Pizzuto, J. Neyts, M.S. Diamond, H.W. Virgin, G. Snell, D. Corti, K. Fink, and D. Veessler. 2020. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. *Science*. 370:950–957.
27. Chi, X., R. Yan, J. Zhang, G. Zhang, Y. Zhang, M. Hao, Z. Zhang, P. Fan, Y. Dong, Y. Yang, Z. Chen, Y. Guo, J. Zhang, Y. Li, X. Song, Y. Chen, L. Xia, L. Fu, L. Hou, J. Xu, C. Yu, J. Li, Q. Zhou, and W. Chen. 2020. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science*. 369:650–655.
 28. Hurlburt, N.K., Y.-H. Wan, A.B. Stuart, J. Feng, A.T. McGuire, L. Stamatatos, and M. Pancera. 2020. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. *bioRxiv*. 2020.06.12.148692.
 29. A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model: Cell. .
 30. Bank, R.P.D. RCSB PDB - 7C8W: Structure of sybody MR17 in complex with the SARS-CoV-2 S receptor-binding domain (RBD). .
 31. Ju, B., Q. Zhang, J. Ge, R. Wang, J. Sun, X. Ge, J. Yu, B. Zhou, S. Song, X. Tang, J. Yu, J. Lan, J. Yuan, H. Wang, J. Zhao, S. Zhang, Y. Wang, X. Shi, and L. Zhang. 2020. Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*. 584:1–8.
 32. Pinto, D., Y.-J. Park, M. Beltramello, A.C. Walls, M.A. Tortorici, S. Bianchi, S. Jaconi, K. Culap, F. Zatta, A.D. Marco, A. Peter, B. Guarino, R. Spreafico, E. Cameroni, J.B. Case, R.E. Chen, C. Havenar-Daughton, G. Snell, A. Telenti, H.W. Virgin, A. Lanzavecchia, M.S. Diamond, K. Fink, D. Veessler, and D. Corti. 2020. Structural and functional analysis of a potent sarbecovirus neutralizing antibody. *bioRxiv*. 2020.04.07.023903.
 33. Piccoli, L., Y.-J. Park, M.A. Tortorici, N. Czudnochowski, A.C. Walls, M. Beltramello, C. Silacci-Fregni, D. Pinto, L.E. Rosen, J.E. Bowen, O.J. Acton, S. Jaconi, B. Guarino, A. Minola, F. Zatta, N. Sprugasci, J. Bassi, A. Peter, A.D. Marco, J.C. Nix, F. Mele, S. Jovic, B.F. Rodriguez, S.V. Gupta, F. Jin, G. Piumatti, G.L. Presti, A.F. Pellanda, M. Biggiogero, M. Tarkowski, M.S. Pizzuto, E. Cameroni, C. Havenar-Daughton, M. Smithy, D. Hong, V. Lepori, E. Albanese, A. Ceschi, E. Bernasconi, L. Elzi, P. Ferrari, C. Garzoni, A. Riva, G. Snell, F. Sallusto, K. Fink, H.W. Virgin, A. Lanzavecchia, D. Corti, and D. Veessler. 2020. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell*. 0.
 34. Custódio, T.F., H. Das, D.J. Sheward, L. Hanke, S. Pazicky, J. Pieprzyk, M. Sorgenfrei, M.A. Schroer, A.Y. Gruzinov, C.M. Jeffries, M.A. Graewert, D.I. Svergun, N. Dobrev, K. Remans, M.A. Seeger, G.M. McInerney, B. Murrell, B.M. Hällberg, and C. Löw. 2020. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. *Nature Communications*. 11:5588.
 35. Song, W., M. Gui, X. Wang, and Y. Xiang. 2018. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. *PLOS Pathogens*. 14:e1007236.
 36. Yuan, Y., D. Cao, Y. Zhang, J. Ma, J. Qi, Q. Wang, G. Lu, Y. Wu, J. Yan, Y. Shi, X. Zhang, and G.F. Gao. 2017. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. *Nature Communications*. 8:15092.
 37. McLellan, J.S., M. Chen, M.G. Joyce, M. Sastry, G.B.E. Stewart-Jones, Y. Yang, B. Zhang, L. Chen, S. Srivatsan, A. Zheng, T. Zhou, K.W. Graepel, A. Kumar, S. Moin, J.C. Boyington, G.Y. Chuang, C. Soto, U. Baxa, A.Q. Bakker, H. Spits, T. Beaumont, Z. Zheng, N. Xia, S.Y. Ko, J.P. Todd, S. Rao, B.S. Graham, and P.D. Kwong. 2013. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. *Science*. 342:592–598.
 38. Chi, X., R. Yan, J. Zhang, G. Zhang, Y. Zhang, M. Hao, Z. Zhang, P. Fan, Y. Dong, Y. Yang, Z. Chen, Y. Guo, J. Zhang, Y. Li, X. Song, Y. Chen, L. Xia, L. Fu, L. Hou, J. Xu, C. Yu, J. Li, Q. Zhou, and W. Chen. 2020. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science*. 369:650–655.
 39. Walke, R.C., J.K. Longworth, R.H. Little, A. Venter, and B.W. Miller. 2004. The practical application of the AMBER software tool to support environmental decision making. *Multimedia Modeling*. 10.

40. Delgado, J., L.G. Radusky, D. Cianferoni, and L. Serrano. 2019. FoldX 5.0: working with RNA, small molecules and a new graphical interface. *Bioinformatics*. 35:4168–4169.
41. Gasteiger, E., C. Hoogland, A. Gattiker, S. Duvaud, M.R. Wilkins, R.D. Appel, and A. Bairoch. 2005. Protein Identification and Analysis Tools on the ExPASy Server. In: Walker JM, editor. *The Proteomics Protocols Handbook*. Totowa, NJ: Humana Press. pp. 571–607.
42. Kawashima, S., P. Pokarowski, M. Pokarowska, A. Kolinski, T. Katayama, and M. Kanehisa. 2008. AAindex: amino acid index database, progress report 2008. *Nucleic Acids Res*. 36:D202-205.
43. Cheng, J., A.Z. Randall, M.J. Sweredoski, and P. Baldi. 2005. SCRATCH: a protein structure and structural feature prediction server. *Nucleic Acids Res*. 33:W72-76.
44. L. Casalino *et al.*, Beyond Shielding: The Roles of Glycans in SARS-CoV-2 Spike Protein. *bioRxiv*, (2020).
45. *Protein structure prediction and analysis using the Robetta server | Nucleic Acids Research | Oxford Academic*.
46. T. Zhou *et al.*, Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains. *bioRxiv*, 2020.2007.2004.187989 (2020).
47. S. M. C. Gobeil *et al.*, D614G mutation alters SARS-CoV-2 spike conformational dynamics and protease cleavage susceptibility at the S1/S2 junction. *bioRxiv*, 2020.2010.2011.335299 (2020).
48. M. C. Gobeil Sophie *et al.*, Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. *Science* **373**, eabi6226.
49. M. J. Abraham *et al.*, GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. *SoftwareX* **1-2**, 19-25 (2015).
50. G. Bussi, D. Donadio, M. Parrinello, Canonical sampling through velocity-rescaling. *The Journal of Chemical Physics* **126**, 014101 (2007).
51. R. Martonák, A. Laio, M. Parrinello, Predicting Crystal Structures: The Parrinello-Rahman Method Revisited. *Physical review letters* **90**, 075503 (2003).
52. Darden, T., D. York, and L. Pedersen. 1993. Particle mesh Ewald: AnN³log(N) method for Ewald sums in large systems. *The Journal of Chemical Physics*. 98(12):10089-10092, doi: 10.1063/1.464397, <https://dx.doi.org/10.1063/1.464397>.
53. Toxvaerd, S., O. J. Heilmann, and J. C. Dyre. 2012. Energy conservation in molecular dynamics simulations of classical systems. *The Journal of Chemical Physics*. 136(22):224106, doi: 10.1063/1.4726728, <https://dx.doi.org/10.1063/1.4726728>.
54. B. Hess, H. Bekker, H. J. C. Berendsen, J. G. E. M. Fraaije, LINCS: A linear constraint solver for molecular simulations. *Journal of Computational Chemistry* **18**, 1463-1472 (1997).
55. Huang, J., S. Rauscher, G. Nawrocki, T. Ran, M. Feig, B. L. de Groot, H. Grubmüller, and A. D. MacKerell. 2017. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. *Nature Methods*. 14(1):71-73, doi: 10.1038/nmeth.4067, <https://www.nature.com/articles/nmeth.4067>